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Polyheterocyclic structures are present in most natural and synthetic 
molecules with important biological activity.[1] Therefore, the 
discovery of new efficient cyclization reactions is important to 
access natural products and to explore a broad range of complex 
scaffolds with potentially enhanced bioactivity.[2] We have recently 
reported the first catalytic formal homo-Nazarov cyclization of vinyl 
cyclopropyl ketones for the synthesis of cyclohexenones (A, 
Scheme 1).[3] In contrast to the well-established Nazarov cyclization 
of divinyl ketones to give cyclopentenones,[4] examples of homo-
Nazarov cyclizations are rare and require stoichiometric amounts of 
strong Lewis acids and/or high temperatures.[5] The mild catalytic 
conditions developed in our work allowed us to apply our method to 
several unprecedented heterocyclic structures, but the scope of the 
reaction was limited by the required presence of an electron-rich 
aromatic group in order to stabilize the formed carbocationic 
intermediate I. 
A heteroatom should also be able to stabilize the formed 
carbocation, as demonstrated by the rich chemistry of donor-
acceptor cyclopropanes.[6] Aminocyclopropanes in particular may 
lead to the fused amino-cyclohexane core of numerous biologically 
relevant alkaloids (R1 = N in Scheme 1). Cyclization of an acyl 
indole substituted amino cyclopropane 1 would constitute a general 
entry into the Aspidosperma alkaloids, such as aspidospermidine (2) 
(B in Scheme 1). The tetracyclic core obtained in the cyclization is 
not only present in the Aspidosperma family, but also in more 
complex natural products such as vinblastine or vincristine, which 
are front-line drugs in cancer therapy.[7] Although the combination 
of synthetically challenging structures and potential medical 
applications has resulted in a large number of successful total 
syntheses of aspidospermidine in the past,[8] the development of 
more general and flexible synthetic approaches is still required in 
order to access new analogs. Herein, we report the first example of 
the formal homo-Nazarov cyclization of aminocyclopropanes and its 
application in the formal total synthesis of aspidospermidine (2). 
Additionally, we demonstrate how a simple modification in reaction 
conditions leads to the scaffold of goniomitine (3), an indole 
alkaloid isolated from the tree Gonioma malagasy,[9] starting from 
aminocyclopropane 1. In contrast to the Aspidosperma scaffold, the 
goniomitine ring system is unique in natural products, and only two 
total syntheses have been reported so far.[9b,9c] Based on our 
cyclization strategy, an efficient total synthesis of goniomitine (3) 
was accomplished and we present here the first study of its 
bioactivity, revealing significant cytotoxicity against several cancer 
cell lines, including vinblastine and taxol resistant P-glycoprotein 
(Pgp, MDR-1) overexpressing cells. 
 
Scheme 1. Formal homo-Nazarov reaction and applications in the 
synthesis of polyheterocyclic natural products. 
We began our research by examining the cyclization of a simple 
model system 4 containing the aminocyclopropane derived from the 
unsubstituted tetrahydro pyridine ring and a N-methylindole 
(Scheme 2).[10] Our standard conditions developed for the catalytic 
homo-Nazarov cyclization were highly successful and the reaction 
occurred in 90% yield with high diastereoselectivity for the cis-
fused product 5.[11] This result demonstrated that carbamates were 
also excellent activating group for the cyclization reaction. 
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Scheme 2. Model study for the cyclization of aminocyclopropane 4. 
Encouraged by this promising result, we then synthesized the 
ethyl substituted cyclopropane 12 required for the core of the 
Aspidosperma alkaloids (Scheme 3). The synthesis of carboxylic 
acid 10 was accomplished using a slightly modified procedure of 
Grieco.[12] δ-Valerolactam (7) was Cbz-protected and alkylated in 
one pot. Reduction and dehydratation led to dehydropiperidine 8. 
Enamide 8 was converted into aminocyclopropane 9 via 
cyclopropanation using CuOTf as catalyst.[13] The low 
diastereoselectivity observed in the cyclopropanation reaction is 
inconsequential, as the diastereomeric mixture of esters equilibrated 
to the exo isomer in presence of BF3.[12] The exo ester obtained was 
hydrolyzed to obtain 10 as a pure diastereoisomer.  
The choice of DMTMM[14] to convert the sensitive 
cyclopropane 10 into Weinreb amide 11 in good yield was crucial. 
The coupling reaction between amide 11 and 2-lithiated N-methyl 
indole afforded the precursor 12 of the homo-Nazarov reaction. To 
our delight, our catalytic conditions for the cyclization gave the 
tetracyclic core of Aspidosperma alkaloids as a single 
diastereoisomer 13 after removal of the Cbz protecting group. 
 
Scheme 3. Synthesis and cyclization of aminocyclopropane 12. 
Reagents and conditions: a) nBuLi, CbzCl, EtI, THF, –78 °C, 67%; b) 
NaBH4, MeOH; c) H2SO4, THF, 93% overall; d) (CuOTf)2•C7H8, 
N2CHCO2Et, DCM, 76% (dr: 1:1); e) BF3•Et2O, DCM; f) NaOH 
H2O/THF/EtOH, 91% overall; e) DMTMM, NMM, THF, 
MeNHOMe•HCl, 93%; h) N-methylindole, nBuLi, tBuOK, THF, 48%; i) 
TsOH, MeCN, quant; j) H2, Pd/C, quant. 
The high diastereoselectivity observed is an important advantage 
of the formal homo-Nazarov cyclization. Other approaches based on 
aminocyclopropanes in intermolecular Friedel-Crafts reactions used 
for the synthesis of Aspidosperma alkaloids proceeded with low 
selectivity.[8d] If an enantioselective cyclopropanation method can be 
developed, an asymmetric synthesis will become possible.[15]  
For the synthesis of aspidospermidine (2) a free NH indole was 
required. Therefore, we investigated the use of bis-lithiated N-
carboxy indoles for the addition reaction to Weinreb amide 11 
(Scheme 4).[16] The interest of carbon dioxide as protecting/directing 
group resides in its easy removal from the product, which already 
occurs upon aqueous work-up. However, its use has been limited to 
simple substrates.[16] We were therefore pleased to observe that the 
coupling procedure proceeded in moderate to good yields, leading 
directly to free NH indole 1a-c. This approach was highly 
convergent and allowed the easy variation of coupling partners for 
the synthesis of analogs.  
 
Scheme 4. Coupling of N-carboxylated indoles. 
The obtained product 1a was submitted to the standard 
conditions for the homo-Nazarov cyclization. We were surprised to 
observe the formation of two different products. The two 
compounds were identified as the desired product 15a resulting 
from cyclization on the C3 position of indole, and the compound 
16a obtained via attack on the N1 position. The cyclic products were 
isolated in 74% yield and a ratio 15a to 16a of 1.6:1 (Table 1, Entry 
1). In order to increase the selectivity for C-C cyclization, we 
examined several Brønsted and Lewis acids as catalysts (Entries 1-
4). The use of soft Lewis acids instead of Brønsted acids allowed the 
preferred formation of 15a as a pure diastereoisomer (Entries 2-3). 
Softer, milder Lewis acids could potentially exert an influence on 
the formation of the acyl iminium intermediate and favour the 
reaction of the softer C3 position of the indole ring. Deprotection of 
15a gave the free amine, concluding the successful formal total 
synthesis of aspidospermidine (2), as this intermediate had already 
been reported by Wenkert.[8d,17] 
The N-cyclization product 16a was also highly interesting, as it 
corresponded to the tetracyclic skeleton of goniomitine (3). When 
considering the rarity of this scaffold, the limited amount of 
synthetic approaches [9b,9c] and the absence of any study on his 
bioactivity, we found worthwhile to optimize the formation of the 
N1-cyclization product 16a. We hypothesized that the use of a less 
polar solvent for the cyclization reaction could enhance the 
reactivity of the iminium intermediate and favorize a fast attack on 
the harder N1 position. Indeed, a strong influence of solvents on the 
cyclization was observed in the presence of Brønsted acids (Table 1, 
Entries 5-8). We were delighted to isolate the goniomitine scaffold 
16a in high yield and excellent selectivity using dichloromethane 
and toluene sulfonic acid as catalyst (Entry 9). 
Cyclizations involving (acyl)iminium ions are important tools in 
the synthesis of alkaloids.[18] Examples involving a possible 
competition between N1 and C3 cyclization are rare, and it is 
difficult to control the regioselectivity and stereoselectivity of these 
reactions.[19] The ring-opening of aminocyclopropanes constitutes a 
new method for the generation of acyl iminium ions and the high 
level of control on the regio- and stereo- selectivity observed is 
unprecedented. To gain a first impression for the generality of the 
method, two methoxy indoles analogs 1b and 1c were examined, as 
similar electron-rich indoles are frequently encountered in natural 
products. Again, high yields and control of regioselectivity were 
achieved in these cases (Table 1, Entries 10-13). 
Table 1. Cyclization of Aminocyclopropanes 1 
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Entry R Catalyst Solvent 15 : 16 Yield 
1 H TsOH MeCN 1.6 : 1[a] 74 
2 H Cu(OTf)2 MeCN 8 : 1
[b] n.d.[c] 
3 H Pd(CH3CN)4(BF4)2 MeCN 11 : 1
[b] n.d. 
4 H Cu(OTf)2 MeCN 7 : 1
[a] 91 
5 H TsOH MeNO2 1.3 : 1
[b] n.d. 
6 H TsOH THF polymers[b] n.d. 
7 H TsOH DCM 1 : 18[b] n.d. 
8 H TsOH Toluene 1 : 16[b] n.d. 
9 H TsOH DCM 1: 21[a] 89 
10 4-OMe TsOH DCM 1 : 22[a] 92 
11 4-OMe Cu(OTf)2 MeCN 8 : 1
[a] 88 
12 5-OMe TsOH DCM 1: 20[a] 86 
13 5-OMe Cu(OTf)2 MeCN 8 : 1
[a] 95 
[a] Yields and ratios obtained from isolated products. Reaction run 
with 1a-c (40-100 mg, 90-250 μmol), 15-25 mol% catalyst and at a 
concentration of 0.025 M. [b] Ratios calculated by integration of 1H 
NMR peaks in the crude mixture. Reaction carried out on a 10 mg (25 
μmol) scale at a concentration of 0.025 M. [c] n.d. = not determined. 
To finish the total synthesis of goniomitine (3) starting from 16a, 
it would be necessary to introduce the lateral chain at C3 in presence 
of the sensitive aminal functionality. In order to avoid this difficult 
task, we envisaged a more convergent approach starting from 
cyclization precursor 1d (Scheme 5). Indole 1d was obtained from 
tryptophol via TIPS protection, carboxylation, lithiation and 
addition to Weinreb amide 11.[20] Cyclopropane 1d was cyclized in 
presence of catalytic amount of TsOH affording the tetracyclic core 
17 of goniomitine (3) in 93% yield. The carbonyl group was reduced 
to the alcohol and acetylated. The acetate and the benzyl carbamate 
were cleaved in one step through hydrogenolysis. Deprotection of 
the primary alcohol gave goniomitine (3) in 77 % overall yield from 
17.[21] The total synthesis of (±)-goniomitine (3) was accomplished 
in a longer linear sequence of 13 steps (5 purifications by column 
chromatography) with an overall yield of 11%. 
 
Scheme 5. Total synthesis of goniomitine (3). Reagents and 
conditions: a) TsOH, CH2Cl2, 93%; b) NaBH4, MeOH; c) Ac2O, 
pyridine; d) Pd/C, H2, EtOH; e) TBAF, THF, 77% overall. 
Somewhat surprisingly, we were unable to find any studies 
about the bioactivity of goniomitine (3). In a first biological 
assessment we therefore investigated the cytotoxicity of this natural 
product. Preliminary results are highly promising as goniomitine 
displays nM antiproliferative effects in several tumor cell lines 
(Table 2). Interestingly, unlike taxol and vinblastine, which are 
approximately 100-fold less effective in P-gp overexpressing cells 
(not shown), goniomitine did not lose its effect in the resistant 
MDR-1-MDCK cell line. 
Table 2. Antiproliferative activity of goniomitine 
Cell Lines IC50
[a] 
A549  205 ± 27 nM 
MCF-7  239 ± 13 nM 
HCT116  281 ± 29 nM 
PC3  159 ± 24 nM 
MDCK 247 ± 10 nM 
MDR-1-MDCK 381 ± 17 nM 
[a] IC50 values for inhibition of human tumor cell growth. A549: lung; 
MCF-7: breast; HCT-116: colon; PC-3M: prostate; MDCK canine 
kidney. MDR-1-MDCK is a human P-glycoprotein 170 (P-gp170)-
overexpressing multidrug-resistant cell line.[22] 
In conclusion, we have demonstrated the versatility of 
aminocyclopropanes as (acyl)iminium precursors for intramolecular 
cyclizations. The reaction proceeded under mild conditions and 
control about the regioselectivity was possible by the right choice of 
catalyst and solvent. The power of the methodology has been 
demonstrated in the efficient formal total synthesis of 
aspidospermidine (2) and the total synthesis of goniomitine (3). 
Preliminary studies on the bioactivity of goniomitine revealed its 
relatively potent cytotoxicity (antiproliferative effect) (IC50: 150-400 
nM) against several tumor cell lines. Preliminary data show that this 
natural product disrupts the microtubule network (not shown). 
Therefore, goniomitine is a potential new anticancer lead structure. 
In the future, the high convergence of our synthetic approach will 
allow us to access a large number of analogs of goniomitine (3) for 
structure-activity relationship studies. Applications of 
aminocyclopropanes as iminium precursors for other types of 
cyclization or addition reactions as well as the development of 
asymmetric cyclopropanation methods for enamides are currently 
under investigation in our laboratory and the results of this work 
will be reported in due course. 
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1 General Methods 
All reactions were carried out in oven dried glassware under an atmosphere of nitrogen, unless stated 
otherwise. For quantitative flash chromatography technical grade solvents were used. For flash 
chromatography for analysis, HPLC grade solvents from Sigma-Aldrich were used. THF, Et2O, CH3CN, 
toluene, hexane and CH2Cl2 were dried by passage over activated alumina under nitrogen atmosphere (H2O 
content < 10 ppm, Karl-Fischer titration). NEt3 and pyridine were distilled under nitrogen from KOH. All 
chemicals were purchased from Acros, AldricH; Fluka, VWR, Aplichem or Merck and used as such unless 
stated otherwise. Chromatographic purification was performed as flash chromatography using Macherey-
Nagel silica 40-63, 60 Å, using the solvents indicated as eluent with 0.1-0.5 bar pressure. The deactivation 
of silica was obtained with a 1% solution of Et3N in the indicated solvent. TLC was performed on Merck 
silica gel 60 F254 TLC glass plates or aluminium plates and visualized with UV light, permanganate stain, 
CAN stain or Anisaldehyde stain. Melting points were measured on a Büchi B-540 melting point apparatus 
using open glass capillaries, the data is uncorrected. 1H-NMR spectra were recorded on a Brucker DPX-400 
400 MHz and a  Brucker AV-500 500 MHz spectrometer in chloroform-d, DMSO-d6 or CD3OD, all signals 
are reported in ppm with the internal chloroform signal at 7.26 ppm, the internal DMSO signal at 2.50 ppm 
or the internal methanol signal at 3.30 ppm as standard. The data is being reported as (s =  singlet, d =  
doublet, t =  triplet, q =  quadruplet, qi =  quintet, m =  multiplet or unresolved, br =  broad signal, app =  
apparent, coupling constant(s) in Hz, integration; interpretation).13C-NMR spectra were recorded with 1H-
decoupling on a Brucker DPX-400 100 MHz and a  Brucker AV-500 125 MHz spectrometer in chloroform-
d, DMSO-d6 or CD3OD, all signals are reported in ppm with the internal chloroform signal at 77.0 ppm, the 
internal DMSO signal at 39.5 ppm or the internal methanol signal at 49.0 ppm as standard. Infrared spectra 
were recorded on a JASCO FT-IR B4100 spectrophotometer with an ATR PRO410-S and a ZnSe prisma 
and are reported as cm-1 (w =  weak, m =  medium, s =  strong, br =  broad). Gas chromatographic and low 
resolution mass spectrometric measurements were performed on a Perkin-Elmer Clarus 600 gas 
chromatographer and mass spectrometer using a Perkin-Elmer Elite fused silica column (length: 30 m, 
diameter: 0.32 mm) and Helium as carrier gas. High resolution mass spectrometric measurements were 
performed by the mass spectrometry service of ISIC at the EPFL on a MICROMASS (ESI) Q-TOF Ultima 
API. HPLC measurement were done on a JASCO HPLC system with an AS2055 Autosampler, a PU 2089 
Pump, a UV 2075 detector and a SEDEX 85 (SEDERE) detector using a CHIRALPAK IC column from 
DAICEL Chemical Industries Ltd. HPLC grade solvents from Sigma-Aldrich were used. 
2 General Procedures 
General procedure 1 (GP1): homo-Nazarov cyclization 
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Toluenesulfonic acid (0.2 equiv) was added to a solution of vinyl cyclopropyl ketone (0.04 M in 
anhydrous CH3CN) at room temperature. The reaction was stirred during the indicated time. The solution 
was quenched with NaHCO3 and extracted with Et2O. The combined organic layers were washed with brine, 
dried over MgSO4 and the solvent was removed under reduced pressure. The crude product was purified as 
indicated. 
General procedure 2 (GP2): nitrogen cyclization 
Toluenesulfonic acid (0.15-0.20 equiv) was added to a solution of vinyl cyclopropyl ketone (0.02 M in 
anhydrous DCM). The reaction was stirred during the indicated time. The solution was quenched with 
NaHCO3 and extracted with Et2O. The combined organic layers were washed with brine, dried over MgSO4 
and the solvent was removed under reduced pressure. The cyclization products are purified as indicated and 
deprotected via GP4 for analysis (Cbz-protected products were difficult to analyze due to the presence of 
rotamers). 
General procedure 3 (GP3): homo-Nazarov cyclization 
A solution of Copper(II) triflate (0.15-0.20 equiv, 0.1 M in anhydrous CH3CN) was added dropwise to a 
solution of a vinyl cyclopropyl ketone derivative (0.02 M in anhydrous CH3CN). The reaction was stirred 
during the indicated time. The solution was quenched with NaHCO3 and extracted with Et2O. The combined 
organic layers were washed with brine, dried over MgSO4 and the solvent was removed under reduced 
pressure. The cyclization products are purified as indicated and deprotected via GP4 for analysis (Cbz-
protected products were difficult to analyze due to the presence of rotamers). 
General procedure 4 (GP4): hydrogenolysis 
To a solution (0.02 M in EtOH) of protected amine at room temperature Pd/C (0.10 equiv) was added 
portionswise. Hydrogen gas was bubbled into the solution until the conversion of all starting material 
(controlled by TLC)[1]. The suspension was filtered on celite (pre-washed with DCM), washed with DCM 
and AcOEt and dried over MgSO4. The organic layer was evaporated on reduced pressure. No further 
purification was needed.  
General procedure 5 (GP5): Carboxylation of indoles 
Using a slight modification of a reported procedure,[2] nBuLi (2.5 M in pentane, 1.2 equiv) was added 
dropwise to a solution of substituted indole (0.2 M in Et2O) at 0°C. The reaction was refluxed 2 hours then 
cooled to 0°C and CO2 was bubbled in the solution during 30 minutes. The suspension was quenched with 
                                                     
[1]  A batch to batch dependency of the reaction time was observed (15 min to 5 h). It is consequently important to monitor the 
reaction carefully via TLC. 
[2] D. A Shirley, P. A. Roussel, J. Am. Chem. Soc. 1953, 75, 375. 
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water and the organic layer was washed several times with water. The aqueous layer was acidified until pH 
= 2 and the precipitate was filtered and dried under vacuum. 
 
3 Substrates synthesis 
3,4-Dihydro-2H-pyridine-1-carboxylic acid benzyl ester (19) 
 
Following a reported procedure,[3] δ-valerolactam (7) (3.00 g, 30.2 mmol, 1.00 equiv) was dissolved in 
THF (130 mL). The reaction mixture was cooled to -78 °C and nBuLi (2.5 M in hexane, 12 mL, 30 mmol, 
1.0 equiv) was added dropwise to the resulting suspension. After 30 min at -78 °C, a solution of 
benzylchloroformate (4.3 mL, 30 mmol, 1.0 equiv) in THF (30 mL) was added dropwise. After 4 h at -78 
°C, the reaction mixture was quenched with sat. NH4Cl (40 mL) and warmed to 23 °C. The reaction mixture 
was extracted with Et2O (3x50 mL). The combined organic layers were washed with brine (50 mL), dried 
over MgSO4 and the solvent was removed under reduced pressure to give the crude Cbz protected lactam 18 
(6.95 g, 29.8 mmol, 99%), which was used without further purification. 
Rf  0.30 (PET/AcOEt 2:1, Anisaldehyde); 
1H NMR (CDCl3, 400 MHz) δ 7.47-7.28 (m, 5 H; PhH), 5.28 (s, 2 H; OCH2), 3.74 (m, 2 H; CH2N), 2.54 
(m, 2 H; CH2CO), 1.83 (m, 4 H; CH2). 
Following a reported procedure,[4] protected lactame 18 (2.82 g, 12.1 mmol, 1.00 equiv) was dissolved in 
methanol (52 mL) at 0 °C and sodium borohydride (0.46 g, 12 mmol, 1.0 equiv) was added portionswise. 
After the end of the addition, the reaction mixture was stirred at 0 °C for 15 min and poured onto ice-water 
(150 mL). The reaction mixture was extracted with AcOEt (3x100 mL). The combined organic layers were 
washed with brine (50 mL), the combined water layers were extracted with AcOEt (100 mL) and the 
combined organic layers were dried over MgSO4 and the solvent was removed under reduced pressure. 
The residues were dried in HV for 15 min and dissolved in THF (25 mL). Conc. sulfuric acid (0.13 mL) 
was added and the reaction was monitored via TLC (PET/AcOEt 10:1-2:1). After 1 h the reaction mixture 
was poured onto sat. NaHCO3 (100 mL) and extracted with AcOEt (3x100 mL). The combined organic 
layers were dried over MgSO4 and the solvent was removed under reduced pressure. The crude product was 
purified by flash column chromatography (PET/AcOEt 10:1-2:1) to yield enamide 19 (1.76 g, 8.11 mmol, 
67%) as a colorless oil.  
                                                     
[3] A. Giovannini, D. Savoia, A. Umani-Ronchi, J. Org. Chem. 1989, 54, 228. 
[4]  Y. Takeuchi, K. Azuma, M. Oshige, H. Abe, H. Nishioka, K. Sasaki, T. Harayama, Tetrahedron 2003, 59, 1639. 
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Rf  0.80 (PET/AcOEt 2:1, Anisaldehyde).  
1H NMR (CDCl3, 400 MHz) δ 7.43-7.27 (m, 5 H; PhH), 6.89 (d, J = 8.6 Hz, 0.4 H; alkene H), 6.80 (d, J 
= 8.6 Hz, 0.6 H; alkene H), 5.18 (s, 2 H; CH2O), 4.97 (m, 0.4 H; alkene H), 4.86 (m, 0.6 H; alkene H), 3.63 
(m, 2 H; CH2N), 2.04 (m, 2 H; CH2), 1.83 (m, 2 H; CH2).  
13C NMR (CDCl3, 100 MHz) (rotamers!) δ 151.7, 136.3, 128.5, 128.5, 128.2, 128.0, 128.0, 125.3, 124.8, 
106.7, 106.4, 67.4, 67.3, 42.3, 42.2, 21.6, 21.4, 21.2.  
IR ν 2951 (w), 1703 (s), 1653 (m), 1409 (s), 1347 (s), 1256 (s), 1227 (m), 1183 (w), 1108 (s), 1054 (m), 
912 (m), 764 (m), 731 (s), 697 (s).  
1H NMR corresponded to the literature values.[4] 
 
2-Benzyl 7-ethyl 2-azabicyclo[4.1.0]heptane-2,7-dicarboxylate (20) and 2-(benzyloxycarbonyl)-2-
azabicyclo[4.1.0]heptane-7-carboxylic acid (21) 
 
Following a reported procedure,[5] a mixture of enamide 19 (1.70 g, 7.82 mmol, 1.00 equiv) and 
copper/bronze (67 mg, prepared freshly as following: Zinc powder (0.20 g) was added to a solution of 
CuSO4•5H2O (1.0 g) in water (2 mL) over 10 min at RT. The resulting suspension was filtered, the solid was 
washed with water (3x5 mL), ethanol (3x5 mL) and Et2O (2x5 mL) and dried 1 h in HV) was heated to 135 
°C. Ethyl diazoacetate (4.2 mL, 40 mmol, 5.0 equiv) was added via syringe pump over 90 min, and the 
reaction was stirred for further 30 min before cooling down to RT. The crude product was purified by two 
successive flash column chromatography (PET/AcOEt 10:1-2:1) to yield cyclopropane 20 (1.18 g, 3.89 
mmol, 50%, Rf = 0.30 (PET/AcOEt 3:1), still containing some polymeric impurities) as a colorless oil. 
The crude ester 20 (1.18 g, 3.89 mmol, 1.00 equiv) was dissolved in ethanol (4 mL) at 0 °C and NaOH 
(2.2 g, 55 mmol, 14 equiv) was added. The reaction mixture was stirred 1 h at 0 °C and 12 h at RT, diluted 
with water (10 mL), acidified to pH = 1 with 1 M HCl and extracted with CH2Cl2 (3x20 mL). The combined 
organic layers were dried over MgSO4 and the solvent was removed under reduced pressure to give nearly 
pure acid 21 (0.89 g, 3.2 mmol, 84%, 42 % from enamide 19) as a colorless oil. 
1H NMR (CDCl3, 400 MHz) δ 7.39-7.26 (m, 5 H; CH-Ar), 5.26-5.11 (m, 2 H; OCH2 ), 3.88 (dt, J = 12.5 
Hz, 3.2 Hz, 0.7 H; NCH2 or NCH rotamer A), 3.74 (s, 0.3 H; NCH2 or NCH rotamer B), 3.57 (m, 0.3 H; 
NCH2 or NCH rotamer B), 3.50 (dd, J = 8.6 Hz, 2.6 Hz, 0.7 H; NCH2 or NCH rotamer A), 2.77 (dd, J = 1.3 
                                                     
[5] P. A. Grieco, M. D. Kaufman, J. Org. Chem. 1999, 64, 7586. 
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Hz, 0.6 Hz, 0.3 H; NCH2 or NCH rotamer B), 2.67 (td, J = 12.5 Hz, 2.2 Hz, 0.7 H; NCH2 or NCH rotamer 
A), 2.08-1.78 (m, 3 H; CHCO and CH2), 1.77-1.58 (m, 2 H; CH or CH2), 1.40-1.20 (m, 1 H; CH or CH2). 
13C NMR (CDCl3, 100 MHz) (rotamers!) δ 178.0, 177.0, 156.4, 136.5, 136.3, 128.8, 128.6, 128.5, 128.3, 
127.7, 127.6, 127.5, 127.2, 126.7, 126.4, 68.4, 67.0, 39.8, 39.7, 38.1, 38.0, 26.5, 26.4, 25.5, 25.4, 22.8, 22.6, 
19.6, 19.4. 
IR ν 3062 (w), 2946 (w), 2870 (w), 1689 (m), 1448 (w), 1423 (m), 1350 (w), 1302 (w), 1266 (m), 1195 
(m), 1135 (w), 1098 (w), 1041 (w), 1002 (w), 909 (w), 731 (s), 699 (s). 
HRMS(ESI) calcd for C15H18NO4+ (M+H) 276.1236, found 276.1232.  
 
Benzyl 7-(methoxy(methyl)carbamoyl)-2-azabicyclo[4.1.0]heptane-2-carboxylate (22) and benzyl 7-
(1-methyl-1H-indole-2-carbonyl)-2-azabicyclo[4.1.0]heptane-2-carboxylate (4) 
 
Following a reported procedure,[6] N-methylmorpholine (0.40 mL, 3.6 mmol, 1.1 equiv) was added to a 
solution of acid 21 (0.90 g, 3.3 mmol, 1.0 equiv) in DMF (3.3 mL) at 0 °C. After 25 min, 
isobutylchloroformate (0.47 mL, 3.6 mmol, 1.1 equiv) was added dropwise at 0 °C. After 10 min, N,O-
dimethylhydroxylamine hydrochloride (0.35 g, 3.6 mmol, 1.1 equiv) was added, followed by N-
methylmorpholine (0.46 mL, 4.2 mmol, 1.3 equiv) and the reaction mixture was warmed to 23 °C. After 12 
h, the reaction was quenched with 0.5 M HCl (6 mL) and extracted with CH2Cl2 (3x10 mL). The combined 
organic layers were washed with 0.5 M NaOH (2x10 mL), brine (10 mL), dried over MgSO4 and the solvent 
was removed under reduced pressure. The crude product was purified by flash column chromatography 
(PET/AcOEt 4:1-1:1) to yield Weinreb amide 22 (665 g, 2.09 mmol, 64%, Rf = 0.30 (PET/AcOEt 1:1) as a 
colorless oil, which was used directly in the next step.  
N-Methyl indole (0.16 mL, 1.2 mmol, 1.2 equiv) was diluted in THF (4 mL) at 0 °C and nBuLi (0.47 mL, 
1.2 mmol, 1.2 equiv) was added dropwise. The reaction mixture was stirred 1 h at RT and cooled to -78 °C. 
Weinreb amide 22 (dried through 3 co-evaporation with toluene, 0.31 g, 0.97 mmol, 1.0 equiv) was added 
dropwise via cannula as a cooled (-78 °C) solution in THF (2 mL). After further stirring 2 h at -78 °C, a 
solution of KOtBu (0.22 g, 2.0 mmol, 2.0 equiv) in THF (2 mL) was added. After 2 h, the reaction mixture 
                                                     
[6]  S. R. Nagarajan, H. F. Lu, A. F. Gasiecki, I. K. Khanna, M. D. Parikh, B. N. Desai, T. E. Rogers, M. Clare, B. B. Chen, M. 
A. Russell, J. L. Keene, T. Duffin, V. W. Engleman, M. B. Finn, S. K. Freeman, J. A. Klover, G. A. Nickols, M. A. Nickols, 
K. E. Shannon, C. A. Steininger, W. F. Westlin, M. M. Westlin, M. L. Williams, Bioorg. Med. Chem. 2007, 15, 3390. 
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was warmed to 0 °C, whereas the yellow suspension became an orange solution. After 5 min at 0 °C, the 
reaction mixture was quenched with sat. NaHCO3 (10 mL) and extracted with Et2O (3x10 mL). The 
combined organic layers were washed with brine (10 mL), dried over MgSO4 and the solvent was removed 
under reduced pressure. The crude product was purified by flash column chromatography (PET/AcOEt 5:1-
3:1) to yield indole 4 (251 mg, 0.646 mmol, 67%) as a colorless solid. 
Rf  0.30 (PET/AcOEt 3:1, Anisaldehyde). 
Mp 119-121 °C. 
1H NMR (CDCl3, 400 MHz) δ 7.70 (d, J = 8.0 Hz, 1 H; CH-Ar), 7.43-7.28 (m, 4 H; CH-Ar), 7.22-7.14 
(m, 1 H; CH-Ar), 7.10-7.02 (m, 2 H; CH-Ar), 6.99-6.89 (m, 2 H; CH-Ar), 5.16 (d, J = 12.5 Hz, 1 H; OCH2), 
4.99 (d, J = 12.5 Hz, 1 H; OCH2), 4.06 (s, 0.8 H; CH3 rotamer B), 4.00 (s, 2.2 H; CH3 rotamer A), 3.95 (t, J 
= 3.8 Hz, 0.8 H; NCH or NCH2 rotamer A), 3.84 (m, 0.2 H; NCH or NCH2 rotamer B), 3.67 (m, 0.2 H; 
NCH or NCH2 rotamer B), 3.55 (dd, J = 8.3 Hz, 2.2 Hz, 0.8 H; NCH or NCH2 rotamer A), 2.85 (t, J = 12.5 
Hz, 0.2 H; NCH or NCH2 rotamer B), 2.76 (td, J = 12.5 Hz, 2.2 Hz, 0.8 H; NCH or NCH2 rotamer B), 2.63 
(dd, J = 5.8 Hz, 2.2 Hz, 1 H; COCH), 2.28 (m, 1 H; CH2CH), 2.06-1.90 (m, 2 H; CH2), 1.81-1.71 (m, 1 H; 
CH2), 1.48 (m, 1 H; CH2). 
13C NMR (CDCl3, 100 MHz) (rotamers!) δ 189.9, 156.4, 140.0, 136.2, 135.4, 128.4, 128.0, 127.5, 127.5, 
126.8, 125.9, 125.7, 125.5, 122.8, 122.6, 120.6, 120.3, 111.3, 111.1, 110.2, 67.1, 65.1, 41.6, 41.0, 33.5, 32.8, 
32.0, 29.6, 23.8, 21.8, 19.9. 
IR ν 2941 (w), 2866 (w), 1702 (s), 1639 (s), 1615 (w), 1513 (m), 1428 (s), 1407 (s), 1347 (s), 1299 (m), 
1264 (m), 1195 (s), 1152 (m), 1129 (s), 1095 (m), 1034 (s), 908 (m), 794 (w), 769 (w), 752 (s), 731 (s), 698 
(s), 648 (w). 
HRMS(ESI) calcd for C24H25N2O3+ (M+H) 389.1865, found 389.1854. 
 
Benzyl 7-methyl-6-oxo-2,3,4,4a,5,6,7,11c-octahydro-1H-pyrido[3,2-c]carbazole-1-carboxylate (5) 
and 7-methyl-3,4,4a,5,7,11c-hexahydro-1H-pyrido[3,2-c]carbazol-6(2H)-one (6) 
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The reaction was performed following GP1, starting from cyclopropane 4 (50 mg, 0.13 mmol, 1.0 equiv) 
and tosic acid (4.9 mg, 0.030 mmol, 0.20 equiv). The reaction was quenched after 12 h. Purification by flash 
chromatography (PET/AcOEt, 3:7) afforded 5 (45 mg, 0.12 mmol, 90 %) as yellow oil. Rf 0.60 (PET/AcOEt 
7:3, Anisaldehyde). The indole derivative 5 (35 mg, 0.090 mmol, 1.0 equiv) was deprotected following 
general procedure GP4, using Pd/C (10 mg, 10% w/w) in Et2O (3.5 mL) and a H2 balloon. The suspension 
was filtered on celite and washed with DCM to afford 6 as yellow oil in quantitative yield (23 mg, 0.090 
mmol, 1.0 equiv). 
Rf 0.80 (DCM/MeOH/Et3N 3:1:2%, Anisaldehyde). 
1H NMR (CDCl3, 400 MHz) 7.88 (d, J = 8.1 Hz, 1 H; Hm or Hh), 7.43-7.31 (m, 2 H; Hm or Hh and Hi or 
Hl), 7.18 (t, J = 7.4 Hz, 1 H; Hi or Hl), 4.35 (d, J = 3.3 Hz, 1 H; Hf), 4.06 (s, 3 H; 3Hg), 3.23 (dd, J = 16.5 
Hz, 12.0 Hz, 1 H; H1e), 2.96 (m, 1 H; H1a), 2.83 (m, 1 H; H2a), 2.52 (m, 1 H; Hd), 2.41 (dd, J = 16.5 Hz, 4.0 
Hz, 1 H; H2e), 1.87-1.60 (m, 4 H; H1c and/or H2c and/or H1b and/or H2b and NH), 1.57-1.45 (m, 1 H; H1b or 
H2b or H1c). 
13C NMR (CDCl3, 100 MHz) δ 192.2, 139.7, 130.2, 126.6, 123.9, 121.4 120.7, 110.3, 110.3, 51.4, 45.3, 
41.0, 35.9, 31.5, 29.7, 28.5. 
IR ν 3299 (w), 2926 (s), 2855 (m), 2149 (w), 1662 (s), 1616 (w), 1469 (m), 1432 (m), 1419 (w), 1386 
(w), 1245 (m), 1062 (w), 758 (s), 746 (s), 732 (w), 655 (m). 
HRMS(ESI) calcd for C16H19N2O+ (M+H) 255.1497, found 255.1490. 
Important correlations ROESY: Hf-Ha2; Hf-Hc2; Hf-Hd; Hf-He2 (see the 2D spectra in section 6)  
 
3,4-Dihydro-2H-3-ethylpyridine-1-carboxylic acid benzyl ester (8) 
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Following a reported procedure,[5] a 2.5 M solution of nBuLi in pentane (88.0 mL, 220 mmol 2.20 equiv) 
was added dropwise to a solution of δ-valerolactam (7) (10.0 g, 100 mmol, 1.00 equiv) in THF (200 mL) at 
0°C. The reaction mixture was stirred during 30 min and distilled ethyl iodide (12.2 mL, 150 mmol, 1.50 
equiv) was added. The solution was stirred for additional 20 minutes before benzylchloroformate (14.9 mL, 
105 mmol, 1.05 equiv) in THF (50 mL) was added. The reaction was stirred further 20 minutes, diluted with  
ether (250 mL) and washed with brine (2x50 mL). The organic layer was dried over magnesium sulfate and 
concentrated under reduced pressure. The crude product was purified by flash column chromatography 
(PET/AcOEt 5:1) to yield lactame 23 (17.4 g, 66.5 mmol, 67%) as colorless oil.  
Rf  0.25 (PET/AcOEt 5:1, Anisaldehyde).  
1H NMR (CDCl3, 400 MHz) δ 7.43 (m, 2H; CH-Ar), 7.39-7.28 (m, 3 H; CH-Ar), 5.27 (s, 2 H; OCH2), 
3.81 (m, 1 H; NCH2), 3.69 (m, 1 H; NCH2), 2.35 (m, 1 H; CHCO), 2.07-1.73 (m, 4 H; CH2CH2), 1.58-1.46 
(m, 2H; CH2CH3), 0.96 (t, J = 7.5 Hz, 3H; CH3).  
Following a reported procedure,[4] sodium borohydride (829 mg, 21.9 mmol, 1.05 equiv) was added 
portionswise into a solution of lactame 23 (5.45 g, 20.9 mmol, 1.00 equiv) in methanol (100 mL) at 0 °C. 
After the end of the addition, the reaction mixture was stirred at 0 °C for 15 min and poured onto ice-water 
(150 mL). The reaction mixture was extracted with AcOEt (3x100 mL). The combined organic layers were 
washed with brine (50 mL), the combined water layers were extracted with AcOEt (100 mL) and the 
combined organic layers were dried over MgSO4 and the solvent was removed under reduced pressure. The 
residue was dissolved in Et2O (50 mL) and 0.5 mL of concentrated sulfuric acid was added dropwise. The 
reaction was stirred at RT for 1 hour then quenched with K2CO3 and dried on Na2SO4.The suspension was 
filtered and concentrated to afford 8 (4.75 g, 19.4 mmol, 93% overall) without further purification as a 
colorless oil.  
Rf 0.36 (PET/AcOEt 9:1, Anisaldehyde). 
1H NMR (CDCl3, 400 MHz) δ 7.42-7.28 (m, 5 H; CH-Ar), 6.70 (s, 0.45 H; alkene-H rotamer A), 6.60 (s, 
0.55 H; alkene-H rotamer B), 5.19 (s, 1.1 H; OCH2 rotamer B), 5.17 (s, 0.9 H; OCH2 rotamer A), 3.57 (m, 2 
H; NCH2), 2.07-1.94 (m, 4 H; allylic CH2), 1.82 (m, 2 H; CH2CH2), 1.06-0.97 (m, 3 H; CH3). 
13C NMR (CDCl3, 100 MHz) (rotamers!) δ 153.4, 153.0, 136.5, 136.4, 128.3, 127.9, 127.8, 121.0, 120.6, 
119.1, 118.7, 67.1, 67.0, 41.9, 41.8, 28.1, 28.1, 24.8, 24.7, 21.6, 21.6, 12.6, 12.4. 
IR ν 2962 (w), 2934 (w), 2880 (w), 1703 (s), 1499 (w), 1409 (s), 1345 (m), 1313 (m), 1258 (s), 1202 
(m), 1176 (m), 1111 (m), 1041 (m), 988 (m), 914 (m), 882 (m), 761 (m), 738 (m), 698 (m), 635 (m), 607 
(m). 
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HRMS(ESI) calcd for C15H20NO2+ (M+H) 246.1494, found 246.1496. 
 
1-Benzyloxycarbonyl-5-ethyl-1-azabicyclo[4.1.0]heptan-7-carboxylic acid ethyl ester (9) 1-
Benzyloxycarbonyl-5-ethyl-1-azabicyclo[4.1.0]heptan-7-carboxylic acid (10) 
 
Following a slight modification of a reported procedure,[7] a solution of ethyl diazoacetate (6.2 mL, 59 
mmol, 4.0 equiv) in DCM (15 mL) was added to a solution of enamine 8 (3.64 g, 14.9 mmol, 1.00 equiv) 
and copper triflate (I) toluene complex (192 mg, 0.370 mmol, 0.0200 equiv) in DCM (15mL) over 18 h (1.3 
mL/h) via syringe pump. After the addition was complete, the reaction was concentrated and purified by 
flash column chromatography (PET/AcOEt 15:1 until PET/AcOEt 9:1) to yield 9 (3.74 g, 11.3 mmol, 76%) 
as colorless oil. Following a reported procedure,[5] the mixture of exo and endo esters (1.50 g, 4.53 mmol, 
1.00 equiv) in dichlorometane (20 mL) at -20°C was treated with BF3•Et2O (96 mg, 0.68 mmol, 0.15 equiv). 
The reaction was allowed to warm at 0°C and stirred at the same temperature until the isomerization was 
finished (from Rf 0.28-0.32 PET/AcOEt 9:1 to Rf 0.30 PET/AcOEt 9:1, Anisaldehyde). Triethylamine (1 
mL) was added dropwise to the reaction and the mixture was diluted with Et2O (50 mL) and washed with 
water and brine. The organic layer was dried over Na2SO4 and evaporated under reduced pressure to give a 
pale yellow oil (1.50 g) which was used directly in the next step.  
The crude oil (1.50 g, 4.53 mmol, 1.00 equiv) was dissolved in a solution of water/THF/EtOH 1/1/3 (25 
mL total) at 0°C and NaOH (1.63 g, 40.3 mmol, 9.00 equiv) was added portionswise. The reaction was 
heated to 60°C and stirred during 2 hours. The solution was concentrated, then diluted with water (30 mL) 
and washed with Et2O (3x20 mL). The aqueous layer was acidified with HCl (1 M aqueous solution) until 
pH 2 and extracted with DCM (3x20 mL) to give 10 as a colorless oil which turns solid upon storage (1.25 
g, 4.12 mmol, 91% overall). No further purification was needed.  
1H NMR (CDCl3, 400 MHz) δ 7.39-7.21 (m, 5 H; CH-Ar), 5.23-5.09 (m, 2 H; OCH2), 3.86 (dt, J = 12.5 
Hz, 3.1 Hz, 0.7 H; NCH2 rotamer A), 3.73 (m, 0.3 H; NCH2 rotamer B), 3.55 (d, J = 3.5 Hz, 0.3 H; NCH 
rotamer B), 3.49 (d, J = 3.6 Hz, 0.7 H; NCH rotamer A), 2.77 (dt, J = 12.5 Hz, 1.7 Hz, 0.3 H; NCH2 rotamer 
B), 2.66 (dt, J = 12.5 Hz, 3.4 Hz, 0.7 H; NCH2 rotamer A), 2.05 (m, 1 H; CHCO), 1.93-1.12 (m, 6 H; CH2), 
0.99 (t, J = 7.2 Hz, 1 H; CH3 rotamer B), 0.93 (t, J = 7.4 Hz, 2 H; CH3 rotamer A). 
                                                     
[7] R. Beumer, C. Bubert, C. Cabrele, O. Vielhauer, M. Pietzsch, O. Reiser, J. Org. Chem. 2000, 65, 8960. 
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13C NMR (CDCl3, 100 MHz) (rotamers!) δ 177.2, 176.9, 156.2, 136.5, 128.5, 128.4, 128.1, 127.7, 127.2, 
67.1, 67.0, 44.9, 44.8, 41.5, 41.1, 34.7, 34.0, 31.1, 30.6, 25.9, 25.7, 21.5, 21.3, 20.9, 10.3, 9.9. 
IR ν 2956 (w), 2939 (w), 2864 (w), 1704 (s), 1584 (w), 1456 (s), 1423 (s), 1348 (m), 1270 (m), 1240 
(m), 1214 (s), 1129 (m), 1036 (m), 1017 (w), 948 (w), 909 (m), 883 (m), 752 (m), 736 (s), 698 (m), 676 (m), 
668 (m), 635 (m). 
HRMS(ESI) calcd for C17H22NO4+ (M+H) 304.1549, found 304.1548. 
 
N-Methoxy-N-methylcarbamo-6-yl-5-ethyl-1-azabicyclo[4.1.0]heptanes-1-benzylcarboxylate (11)  
 
Dimethoxytriazin-N-methylmorpholinium chloride[8] (DMTMM, 900 mg, 3.24 mmol, 1.50 equiv) was 
suspended into a solution of acid 10 (655 mg, 2.16 mmol, 1.00 equiv) in THF (7.5 mL) and the reaction 
mixture was stirred at RT during 60 min. N,O-dimethylhydroxylamine hydrochloride (97.5 mg, 2.16 mmol, 
1.00 equiv) was added, followed by N-methylmorpholine (475 μL, 4.32 mmol, 2.00 equiv) and the reaction 
mixture was stirred during 36 hours. The reaction was quenched with a 5% aqueous solution of citric acid 
and extracted with Et2O. The combined organic layers were dried over MgSO4 and the solvent was removed 
under reduced pressure. The crude reaction mixture was purified by flash column chromatography 
(AcOEt/PET 3:7) to afford 11 (695 mg, 2.00 mmol, 93%) as colorless oil.  
Rf 0.30 (PET/AcOEt 7:3, Anisaldehyde).  
1H NMR (CDCl3, 400 MHz) δ 7.35-7.19 (m, 5 H; CH-Ar), 5.23 (d, J = 12.9 Hz, 0.8 H; OCH2 rotamer 
A), 5.14 (d, J = 12.5 Hz, 0.2 H; OCH2 rotamer B), 5.07 (d, J = 13.0 Hz, 1 H; OCH2), 3.84 (dt, J = 12.5 Hz, 
3.4 Hz, 0.8 H; NCH2 rotamer A), 3.71 (m, 0.2 H; NCH2, rotamer B), 3.64 (s, 0.6 H; OCH3 rotamer B), 3.58-
3.52 (m, 2.4 H; OCH3 rotamer A and NCH rotamer B), 3.49 (d, J = 3.7 Hz, 0.8 H; NCH rotamer A), 3.15 (s, 
0.6 H; NCH3 rotamer B), 3.12 (s, 2.4 H; NCH3 rotamer A), 2.73 (t, J = 11.7 Hz, 0.2 H; NCH2 rotamer B), 
2.64 (dt, J = 12.5 Hz,  2.2 Hz, 0.8 H; NCH2 rotamer A), 2.09-1.87 (m, 2 H; CHCO and CH2), 1.77-1.54 (m, 
4 H; CH2), 1.36 (m, 1 H; CH2), 0.85 (t, J = 7.4 Hz, 3 H; CH3). 
                                                     
[8]  M. Kunishima, C. Kawachi, F. Iwasaki, K. Terao, S. Tani, Tetrahedron Letters 1999, 40, 5327. 
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13C NMR (CDCl3, 100 MHz) δ (rotamers!) 171.2, 156.2, 136.8, 128.2, 128.1, 127.8, 127.8, 127.4, 127.0, 
66.8, 66.5, 61.2, 42.9, 42.7, 41.5, 41.0, 33.0, 32.4, 29.1, 28.5, 26.0, 25.9, 25.2, 21.6, 10.3.  
IR ν 2964 (w), 2937 (w), 2876 (w), 1703 (s), 1651 (s), 1458 (m), 1417 (s), 1384 (m), 1358 (m), 1344 (m) 
(m), 1295 (m), 1266 (m), 1209 (m), 1180 (m), 1123 (m), 1016 (m), 913 (m), 769 (w), 734 (s), 700 (w). 
HRMS(ESI) calcd for C19H27N2O4+ (M+H) 347.1971, found 347.1978. 
 
6-(1-Methyl-1H-indol-2-carbonyl)-5-ethyl-1-azabicyclo[4.1.0]heptane-1-benzylcarboxylate (12) 
N
Cbz
11
O
NO
N
Cbz
12
O
N
N
n-BuLi, tBuOK, THF
 
A solution of N-methylindole (13 μL, 0.10 mmol, 1.3 equiv) in THF (0.5 mL) was stirred at 0° C. Then a 
solution of nBuLi (2.5 M in pentane, 38 μL, 0.10 mmol, 1.2 equiv) diluted in THF (0.2 mL) was added 
dropwise. The solution was warmed to RT, stirred for 1 hour and then cooled to -78° C. From a separate 
flask, a solution of Weinreb amide 11 (27 mg, 0.080 mmol, 1.0 equiv) in THF (0.4 mL) was added via 
cannula into the solution. The mixture was stirred 2 hours at -78° C, then a solution of tBuOK in THF (0.3 
mL) was added dropwise. The reaction was stirred 2 hours at -78° C and 5 min at 0° C, quenched with 
NaHCO3 and extracted with Et2O (5x3 mL). The organic layers were dried over Na2SO4, evaporated on 
reduced pressure and purified on flash chromatography (AcOEt/PET 1:5) to give 12 (16 mg, 0.038 mmol 
48%) as a yellow oil.  
Rf 0.60 (PET/AcOEt 7:3, Anisaldehyde).  
1H NMR (CDCl3, 400 MHz) δ 7.70 (d, J = 8.1 Hz, 1 H; CH-Ar), 7.45-7.29 (m, 4 H; CH-Ar), 7.25-7.00 
(m, 5 H; CH-Ar), 5.19 (d, J = 12.7 Hz, 1 H; OCH2), 5.04 (d, J = 12.7 Hz, 1 H; OCH2), 4.08 (s, 0.6 H; CH3 
rotamer B), 3.97 (s, 2.4 H; CH3 rotamer A), 3.95 (dt, J = 13.2 Hz, 3.4 Hz, 0.8 H; NCH2, rotamer A), 3.88-
3.82 (m, 0.2 H; NCH2, rotamer B), 3.77 (d, J = 3.4 Hz, 1 H; NCH), 2.83 (t, J = 11.9 Hz, 0.2 H; NCH2, 
rotamer B), 2.74 (dt, J = 12.0 Hz, 1.9 Hz, 0.8 H; NCH2, rotamer A), 2.68 (d, J = 3.1 Hz, 0.2 H; COCH; 
rotamer B), 2.65 (d, J = 3.6 Hz, 0.8 H; COCH; rotamer A), 2.18 (m, 1 H; CH2), 1.90-1.48 (m, 5 H; CH2), 
0.85 (t, J = 7.4 Hz, 3 H; CH3).  
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13C NMR (CDCl3, 100 MHz) (rotamers!) δ 190.8, 157.3, 140.9, 137.6, 137.5, 129.4, 129.1, 128.5, 128.2, 
126.9, 126.6, 126.3, 123.7, 121.7, 111.7, 111.3, 67.9, 46.2, 45.9, 42.3, 42.6, 39.2, 38.8, 38.4, 33.0, 27.3, 
27.0, 26.0, 23.0, 22.8 11.7, 11.5.  
IR ν 3064 (w), 3033 (w), 2938 (w), 2876 (w), 1703 (s), 1646 (s), 1614 (w), 1512 (m), 1464 (s), 1428 (s), 
1408 (s), 1348 (s), 1268 (m), 1211 (s), 1196 (s), 1163 (m), 1129 (m), 1049 (m), 1027 (m), 910 (m), 769 (m), 
737 (s), 698 (m).  
HRMS(ESI) calcd for C26H29N2O3+ (M+H) 417.2178, found 417.2181. 
Benzyl 4a-ethyl-7-methyl-6-oxo-2,3,4,4a,5,6,7,11c-octahydro-1H-pyrido[3,2-c]carbazole-1-
carboxylate (24) and  4a-ethyl-7-methyl-3,4,4a,5,7,11c-hexahydro-1H-pyrido[3,2-c]carbazol-6(2H)-one 
(13) 
 
The reaction was performed following general procedure GP1, starting from cyclopropane 12 (14 mg, 
0.034 mmol, 1.0 equiv) and tosic acid (1 mg, 7 μmol, 0.2 equiv). The reaction was quenched after 5 min to 
give 24 (14 mg, 0.034 mmol, quant) without further purification as yellow oil (Rf 0.65 (PET/AcOEt 7:3, 
Anisaldehyde)). The indole derivative 24 (14 mg, 34 μmol, 1.0 equiv) was deprotected following general 
procedure GP2, using Pd/C (3 mg 10% w/w) in Et2O (1.5 mL) and H2 balloon.  The suspension was filtered 
on celite and washed with DCM to afford 13 as green oil in quantitative yield (9.6 mg, 34 μmol). 
Rf 0.75 (DCM/MeOH/Et3N 3:1:2%, Anisaldehyde). 
1H NMR (CDCl3, 400 MHz) δ 8.01 (d, J = 8.2 Hz, 1 H; CH-Ar), 7.45-7.32 (m, 2 H; CH-Ar), 7.22 (t, J = 
7.2 Hz, 1 H; CH-Ar), 4.16 (s, 1 H; CHN), 4.08 (s, 3 H; NCH3), 3.53 (d, J = 17.0 Hz, 1 H; CH2CO), 2.52 (m, 
J = 14.6 Hz, 2 H; CH2N), 2.26 (d, J = 16.8 Hz, 1 H; CH2CO), 1.87-1.21 (m, 7 H; CH2 and NH), 0.75 (t, J = 
7.4 Hz, 3 H; CH3). 
13C NMR (CDCl3, 100 MHz) δ 191.6, 139.8, 129.9, 126.6, 124.3, 121.5, 120.8, 110.3, 110.3, 55.6, 45.0, 
44.0, 40.2, 32.6, 31.6, 31.2, 29.7, 27.5. 
IR ν 3300 (w), 2960 (m), 2935 (m), 2902 (w), 1702 (s), 1662 (s), 1615 (w), 1601 (w), 1542 (w), 1448 
(m), 1411 (m), 1314 (m), 1252 (m), 1179 (w), 1117 (w), 1070 (w), 751 (m), 698 (m), 641 (m), 627 (m), 607 
(m).  
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HRMS(ESI) calcd for C18H23N2O+ (M+H) 283.1810, found 283.1813. 
6-(1H-indol-2-carbonyl)-5-ethyl-1-azabicyclo[4.1.0]heptane-1-benzylcarboxylate (1a) 
 
 
tBuLi (1.6 M in pentane, 38 μL, 0.80 mmol, 2.2 equiv) was added dropwise into a solution of 
carboxylindole 14a prepared following GP5 (64 mg, 0.40 mmol, 1.1 equiv) and LiCl[9] (17 mg, 0.40 mmol, 
1.1 equiv) in THF (1 mL) at -78° C. The solution was stirred for 3 hours and then transferred via cannula 
into a solution of amide 11 (125 mg, 360 μmol, 1.00 equiv) in THF (1 mL) at -78°C. The reaction was 
allowed to warm to -20°C over 5 hours then transferred via cannula into saturated aqueous NaHCO3 solution 
(10 mL) at 0°C. The aqueous phase was extracted with Et2O (5x10 mL). The organic layers were dried over 
Na2SO4, evaporated under reduced pressure and purified on flash chromatography with deactivated silica 
(AcOEt/PET 1:9) to give 1a (97 mg, 24 mmol, 67%) as yellow oil. 
Rf 0.70 (PET/AcOEt 7:3, Anisaldehyde).  
1H NMR (CDCl3, 400 MHz) δ 9.39 (d, J = 0.4 Hz, 0.2 H; NH rotamer B), 9.29 (m, 0.8 H; NH rotamer 
A), 7.72 (d, J = 8.0 Hz, 1 H; CH-Ar), 7.45 (m, 1 H; CH-Ar), 7.36 (m, 2 H; CH-Ar), 7.16 (m, 4 H; CH-Ar), 
7.02 (m, 2 H; CH-Ar), 5.21-5.08 (m, 0.4 H; OCH2 rotamer B), 5.15 (d, J = 12.7 Hz, 0.8 H; OCH2 rotamer A) 
5.02 (d, J = 12.7 Hz, 0.8 H; OCH2 rotamer A), 3.93 (m, 1 H; NCH2), 3.81 (d, J = 3.3 Hz, 1 H; NCH), 2.84 (t, 
J = 12.2 Hz, 0.2 H; NCH2 rotamer B), 2.75 (t, J = 12.1 Hz, 0.8 H; NCH2 rotamer A), 2.61 (d, J = 3.3 Hz, 1 
H; COCH), 2.15 (m, 1 H; CH2), 1.77 (m, 4 H; CH2), 1.54 (m, 1 H; CH2), 0.91 (m, 0.6 H; CH3 rotamer B), 
0.82 (t, J = 7.3 Hz, 2.4 H; CH3 rotamer A). 
13C NMR (CDCl3, 100 MHz) (rotamers!) δ 188.6, 156.3, 137.1, 136.6, 136.5, 128.5, 128.1, 128.1, 127.7, 
127.5, 127.3, 126.1, 122.9, 122.7, 120.9, 120.7, 112.1, 108.6, 108.4, 66.9, 46.0, 45.6, 41.7, 41.3, 38.3, 36.7, 
36.0, 26.3, 26.1, 25.0, 21.9, 21.8, 10.7, 10.6. 
IR ν 3309 (w), 2960 (w), 2936 (w), 2876 (w), 1700 (s), 1629 (s), 1521 (m), 1446 (m), 1409 (s), 1349 (s), 
1313 (w), 1299 (w), 1268 (m), 1232 (w), 1210 (m), 1192 (m), 1164 (m), 1140 (s), 1080 (w), 1034 (w), 1010 
(w), 978 (w), 911 (m), 799 (w), 746 (s), 736 (s), 698 (m), 606 (w). 
                                                     
[9] LiCl was dried under HV (< 0.05 Torr), warmed at 600° C (Mp) and stirred. It was then cooled down to RT and dissolved 
into 1mL of dry THF.  
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HRMS(ESI) calcd for C25H27N2O3+ (M+H) 403.2022, found 403.2034. 
Benzyl 4a-ethyl-6-oxo-2,3,4,4a,5,6,7,11c-octahydro-1H-pyrido[3,2-c]carbazole-1-carboxylate (15a); 
4a-ethyl-7-3,4,4a,5,7,11c-hexahydro-1H-pyrido[3,2-c]carbazol-6(2H)-one (25a); benzyl 4a-ethyl-6-oxo-
2,3,4,4a,5,6-hexahydroindolo[1,2-a][1,8]naphthyridine-1(12aH)-carboxylate (16a); 4a-ethyl-
1,2,3,4,4a,5-hexahydroindolo[1,2-a][1,8]naphthyridin-6(12aH)-one (26a)  
 
The reaction was performed following general procedure GP1, starting from cyclopropane 1a (35 mg, 
0.087 mmol, 1.0 equiv) and tosic acid (3.0 mg, 16 μmol, 0.20 equiv). The reaction was quenched after 15 
min and the crude oil was purified by column chromatography (PET/AcOEt 9:1, Anisaldehyde) to give the 
product 15a (Rf  0.65, 16 mg, 39 μmol, 45 %) and the product 16a (Rf 0.75, 10 mg, 25 μmol, 29%). The 
tetracyclic compound 15a (16 mg, 16 μmol, 1.0 equiv) was deprotected following the general procedure 
GP4 to give 25a (10 mg, 38 μmol, 97 %) as a yellow oil without further purification. Product 16a (10 mg, 
25 μmol, 1.0 equiv) was deprotected following the general procedure GP4 to give 26a (6.7 mg, 25 μmol, 99 
%) as a yellow oil without further purification. 
The reaction was performed using general procedure GP2, starting from cyclopropane 1a (100 mg, 0.250 
mmol, 1.00 equiv) and copper (II) triflate (9.0 mg, 25 μmol, 0.10 equiv). The reaction was quenched after 15 
min and the crude oil was purified by column chromatography (PET/AcOEt 7:3, Anisaldehyde) to give the 
product 15a (Rf  0.65, 80 mg, 0.20 mmol, 80 %) and the product 16a (Rf 0.75, 11 mg, 30 μmol, 11%). The 
tetracyclic compound 15a (70 mg, 0.17 mmol, 1.0 equiv) was deprotected following the general procedure 
GP4 to give 25a (45 mg, 0.17 mmol, quant.) as a yellow oil without further purification. 
The reaction was performed following general procedure GP3, starting from cyclopropane 1a (0.10 g, 0.25 
mmol, 1.0 equiv) and tosic acid (4.7 mg, 25 μmol, 0.1 equiv). The reaction was quenched after 15 min and 
the crude oil was purified by column chromatography (PET/AcOEt 7:3, Anisaldehyde) to give the product 
15a (Rf 0.65, 4.0 mg, 10 μmol, 4 %) and the product 16a (Rf 0.75, 85 mg, 0.22 mmol, 85 %). The tetracyclic 
compound 16a (50 mg, 0.12 mmol, 1.0 equiv) was deprotected following the general procedure GP4 to give 
26a (33 mg, 0.12 mmol, quant.) as a yellow oil without further purification. 
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25a 
Rf 0.0 (AcOEt/PET 6:4, Anisaldehyde). 
1H NMR (CD3OD, 400 MHz) δ 7.91 (d, J = 8.2 Hz, 1 H; CH-Ar), 7.51 (d, J = 8.4 Hz, 1 H; CH-Ar), 7.40 
(d, J = 7.2 Hz, 1 H; CH-Ar), 7.23 (t, J = 7.5 Hz, 1 H; CH-Ar), 4.61 (s, 1 H; CHN), 3.40-3.11 (m, 3 H; CH2N 
and CH2CO), 2.37 (d, J = 17.6 Hz, 1 H; CH2CO), 2.16 (s, 1 H; NH), 1.92 (m, 2 H; CH2), 1.80 (m, 2 H; 
CH2), 1.45 (m, 2 H; CH2), 0.83 (t, J = 7.5 Hz, 3 H; CH3). 
13C NMR (CD3OD, 100 MHz) δ 191.2, 140.0, 132.6, 128.2, 126.1, 122.4, 122.0, 121.6, 114.1, 55.6, 
45.3, 42.7, 41.5, 33.0, 32.7, 20.4, 7.8. 
IR ν 2961 (s), 2943 (s), 2866 (s), 2142 (m), 1660 (w), 1543 (w), 1493 (m), 1464 (m), 1366 (w), 1263 
(w), 1167 (m), 1105 (m), 1073 (m), 1021 (m), 884 (m), 804 (m), 751 (m), 673 (s), 635 (s). 
HRMS(ESI) calcd for C17H21N2O+ (M+H) 269.1654, found 269.1655. 
In order to obtain a crystalline compound, a solution of 25a was treated with an excess of HCl (4 M in 
dioxane). The solvents were removed under reduced pressure and the colorless solid obtained was 
recrystallized by slow diffusion of hexane into a solution in dichloromethane. For X-ray image see the 
spectra in section 6 (CCDC number: 777832). 
26a 
Rf 0.4 (AcOEt/PET 3:7 Anisaldehyde). 
1H NMR (CD3OD, 400 MHz) δ 7.71 (d, J = 8.1 Hz, 1 H; Hh), 7.63 (d, J = 8.4 Hz, 1 H; Hm), 7.43 (t, J = 
7.9 Hz, 1 H; Hi or Hl), 7.28 (s, 1 H; Hg), 7.18 (t, J = 7.7 Hz, 1 H; Hi or Hl), 5.22 (s, 1 H; Hf), 3.36 (d, J = 
17.6 Hz, 1 H; He2), 3.12 (m, 1 H; Ha2), 2.97 (m, 1 H; Ha1), 2.32 (d, J = 17.6 Hz, 1 H; He1), 1.87-1.60 (m, 5 H; 
Hb1 ; Hb2 ; Hc1; Hc2  and NH), 1.31 (q, J = 7.6 Hz, 2 H; 2Hn), 0.80 (t, J = 7.5 Hz, 3 H; 3Ho). 
13C NMR (CD3OD, 100 MHz) δ 192.9, 138.5, 133.1, 128.6, 127.5, 124.3, 122.8, 111.7, 107.4, 70.7, 
45.9, 41.4, 40.2, 33.6, 31.6, 22.1, 7.4. 
IR ν 2934 (w), 2861 (w), 1676 (s), 1532 (s), 1446 (w), 1407 (w), 1360 (w), 1322 (m), 1247 (w), 1196 
(w), 1173 (w), 1146 (w), 1119 (w), 1044 (w), 929 (w), 894 (w), 872 (w), 846 (w), 811 (w), 740 (m), 634 
(w). 
HRMS(ESI) calcd for C17H21N2O+ (M+H) 269.1654, found 269.1652. 
Important correlations NOESY: Hf-Ha1; Hf-2Hn; Hf-3Ho; Hf-He1; Hf-Hm (see the 2D spectra in section 6) 
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6-(5-methoxy-1H-indol-2-carbonyl)-5-ethyl-1-azabicyclo[4.1.0]heptane-1-benzylcarboxylate (1b) 
 
tBuLi (1.6 M in pentane, 0.65 mL, 1.0 mmol, 2.6 equiv) was added dropwise into a solution of 5-metoxy-
carboxylindole 14b (100 mg, 0.520 mmol, 1.30 equiv) prepared following GP5 and LiCl[9] (44.0 mg, 1.04 
mmol, 2.60 equiv) in THF (3.5 mL) at -78° C. The solution was stirred over 3 hours then transferred via 
cannula into a solution of amide 11 (139 mg, 0.400 mmol, 1.00 equiv) in THF (3.5 mL) at 0°C over 20 
minutes. The reaction was stirred at 0°C over 20 minutes then transferred via cannula into a saturated 
aqueous solution of NaHCO3 (10 mL) at 0°C. The aqueous layer was extracted with Et2O (5x10 mL). The 
organic layers were dried over Na2SO4, evaporated under reduced pressure and purified on flash 
chromatography with deactivated silica (AcOEt/toluene 1:9) to give 1b (99.8 mg, 23.0 mmol, 58%) as a 
yellow oil with tendency to solidify and amide 11 (53 mg, 0.15 mmol, 38%). 
Rf 0.25 (AcOEt/toluene 9:1, Anisaldehyde).  
1H NMR (CDCl3, 400 MHz) δ 9.82 (s, 0.8 H; NH rotamer A), 9.74 (s, 0.2 H; NH rotamer B), 7.58-6.92 
(m, 9 H; CH-Ar), 5.32-5.10 (m, 0.4 H; OCH2 rotamer B), 5.17 (d, J = 12.8 Hz, 0.8 H; OCH2 rotamer A), 
5.03 (d, J = 12.6 Hz, 0.8 H; OCH2 rotamer A), 3.98 (m, 1 H; NCH2), 3.92-3.83 (m, 4 H; OCH3 and NCH), 
2.87 (t, J = 11.5 Hz, 0.2 H; NCH2 rotamer B), 2.78 (t, J = 11.9 Hz, 0.8 H; NCH2 rotamer A), 2.64 (d, J = 3.2 
Hz, 1 H; COCH), 2.17 (m, 1 H; CH2), 1.94-1.73 (m, 4 H; CH2), 1.58 (m, 1 H; CH2), 0.85 (t, J = 6.9 Hz, 3 H; 
CH3) 
13C NMR (CDCl3, 100 MHz) (rotamers!) δ 188.6, 156.3, 154.6, 137.1, 136.4, 132.9, 128.4, 128.2, 128.0, 
127.9, 127.4, 127.2, 118.0, 117.7, 117.4, 112.9, 112.9, 109.7, 108.3, 108.0, 102.9, 67.2, 66.9, 55.6, 45.9, 
45.3, 41.7, 41.2, 38.1, 36.7, 36.0, 26.3, 26.0, 25.0, 21.9, 10.7. 
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IR ν 3303 (w), 2941 (w), 2866 (w), 1778 (w), 1703 (m), 1626 (m), 1525 (s), 1458 (m), 1414 (m), 1352 
(m), 1296 (w), 1269 (w), 1211 (s), 1171 (m), 1124 (m), 1029 (w), 911 (w), 742 (m), 677 (w), 630 (w). 
HRMS(ESI) calcd for C26H29N2O4+ (M+H) 433.2127, found 433.2113. 
 
Benzyl ethyl-10-methoxy-6-oxo-2,3,4,4a,5,6,7,11c-octahydro-1H-pyrido[3,2-c]carbazole-1-carboxylate 
(15b); ethyl-10-methoxy-3,4,4a,5,7,11c-hexahydro-1H-pyrido[3,2-c]carbazol-6(2H)-one (25b); benzyl 
4a-ethyl-9-methoxy-6-oxo-2,3,4,4a,5,6-hexahydroindolo[1,2-a][1,8]naphthyridine-1(12aH) carboxylate 
(16b) and 4a ethyl-9-methoxy-1,2,3,4,4a,5-hexahydroindolo[1,2-a][1,8]naphthyridin-6(12aH)-one (26b)  
 
 
NCbz
15b
GP4
ON
H
HN
25b
ON
H
H H
16b
N
Cbz
1b
O
HN
GP4N
N
O
Cbz
H
26b
N
HN
O
H
GP1 or GP2
OMe
MeO
MeO MeO
MeO
 
The reaction was performed using general procedure GP2, starting from cyclopropane 1b (74 mg, 0.17 
mmol, 1.0 equiv) and copper (II) triflate (9.2 mg, 25 μmol, 0.15 equiv). The reaction was quenched after 15 
min and the crude oil was purified by column chromatography (PET/AcOEt 8:2, Anisaldehyde) to give the 
product 15b (Rf 0.3, 62 mg, 0.14 mmol, 84 %) and the product 16b (Rf 0.4, 8.0 mg, 80 μmol, 11%). The 
tetracyclic compound 15b (50 mg, 0.12 mmol, 1.0 equiv) was deprotected following the general procedure 
GP4 to give 25b (35 mg, 0.12 mmol, quant.) as a yellow oil without further purification. 
The reaction was performed following general procedure GP3, starting from cyclopropane 1b (67 mg, 0.16 
mmol, 1.0 equiv) and tosic acid (4.0 mg, 23 μmol, 0.15 equiv). The reaction was quenched after 15 min and 
the crude oil was purified by column chromatography (PET/AcOEt 8:2, Anisaldehyde) to give the product 
15b (Rf 0.3, 3 mg, 7 μmol, 4 %) and the product 16b (Rf 0.4, 55 mg, 0.13 mmol, 82%). The tetracyclic 
compound 16b (53 mg, 0.12 mmol, 1.0 equiv) was deprotected following the general procedure GP4 to give 
26b (36 mg, 0.12 mmol, quant.) as a yellow oil without further purification. 
25b 
Rf 0.0 (AcOEt/PET 6:4 Anisaldehyde). 
1H NMR (CDCl3, 400 MHz) δ 9.29 (s, 1 H; NH indole), 7.30 (d, J = 9.0 Hz, 1 H; CH-Ar), 7.15 (s, 1 H; 
CH-Ar), 7.01 (dd, J = 8.9 Hz, 1.9 Hz, 1 H; CH-Ar), 4.01 (s, 1 H; CHN), 3.86 (s, 3 H; OCH3), 3.16 (d, J = 
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16.8 Hz, 1 H; CH2CO), 3.06 (m, 1 H; CH2N), 2.83 (m, 1 H; CH2N), 2.27 (d, J = 16.8 Hz, 1 H; CH2CO), 1.92 
(br s, 1 H; NH amine), 1.79-1.62 (m, 2 H; CH2), 1.52 (m, 2 H; CH2), 1.42-1.17 (m, 2 H; CH2), 0.81 (t, J = 
7.5 Hz, 3 H; CH3). 
13C NMR (CDCl3, 100 MHz) δ 191.4, 154.7, 133.6, 131.0, 127.5, 125.9, 118.5, 113.6, 100.9, 56.4, 55.7, 
45.4, 42.8, 40.7, 33.0, 31.0, 22.7, 7.7. 
IR ν 3281 (w), 2936 (w), 2857 (w), 1652 (s), 1540 (w), 1487 (m), 1464 (w), 1439 (w), 1335 (w), 1297 
(w), 1264 (m), 1218 (s), 1169 (m), 1121 (w), 1105 (w), 1030 (w), 909 (m), 809 (w), 733 (s), 628 (w).  
HRMS(ESI) calcd for C18H23N2O+ (M+H) 299.1760, found 299.1755. 
 
26b 
Rf 0.2 (AcOEt/PET 4:6 Anisaldehyde). 
1H NMR (CDCl3, 400 MHz) δ 7.31 (d, J = 9.0 Hz, 1 H; CH-Ar), 7.19 (s, 1 H; CH-Ar), 7.10 (d, J = 2.0 
Hz, 1 H; CH-Ar), 7.06 (dd, J = 9.0 Hz, 2.3 Hz, 1 H; CH-Ar), 4.91 (s, 1 H; CHN), 3.85 (s, 3 H; OCH3), 3.32 
(d, J = 17.0 Hz, 1 H; CH2CO), 3.13 (m, 1 H; CH2N), 2.87 (td, J = 11.6 Hz, 2.5 Hz, 1 H; CH2N), 2.30 (d, J = 
17.0 Hz, 1 H; CH2CO), 1.88-1.50 (m, 5H; CH2 and NH), 1.32 (m, 2 H; CH2), 0.81 (t, J = 7.5 Hz, 3 H; CH3). 
13C NMR (CDCl3, 100 MHz) δ 190.7, 155.0, 132.6, 132.1, 127.6, 118.0, 110.6, 105.3, 103.0, 70.7, 55.6, 
45.4, 40.7, 39.2, 33.0, 30.3, 21.8, 7.2. 
IR ν 2931 (w), 2862 (w), 2834 (w), 1672 (s), 1531 (s), 1447 (m), 1406 (w), 1351 (w), 1316 (w), 1267 
(w), 1223 (s), 1179 (m), 1120 (w), 1032 (w), 918 (w), 860 (w), 845 (w), 799 (m), 740 (s). 
HRMS(ESI) calcd for C18H23N2O2+ (M+H) 299.1760, found 299.1749. 
 
6-(4-methoxy-1H-indol-2-carbonyl)-5-ethyl-1-azabicyclo[4.1.0]heptane-1-benzylcarboxylate (1c) 
 
 
tBuLi (1.6 M in pentane, 0.65 mL, 1.0 mmol, 2.6 equiv) was added dropwise into a solution of 4-metoxy-
carboxylindole 14c (100 mg, 0.520 mmol, 1.30 equiv) prepared following GP5 and LiCl[9] (44 mg, 1.0 
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mmol, 2.6 equiv) in THF (3.5 mL) at -78° C. The solution was stirred over 3 hours then transferred via 
cannula into a solution of amide 11 (139 mg, 0.400 mmol, 1.00 equiv) in THF (3.5 mL) at 0°C over 25 
minutes. The reaction was stirred at 0°C over 25 minutes then transferred via cannula into a saturated 
aqueous solution of NaHCO3 (10 mL) at 0°C. The aqueous layer was extracted with Et2O (5x10 mL). The 
organic layers were dried over Na2SO4, evaporated under reduced pressure and purified on flash 
chromatography with deactivated silica (AcOEt/toluene 1:9) to give 1c (86 mg, 20 mmol, 50%) as a yellow 
oil with tendency to solidify. 
Rf 0.20 (AcOEt/PET 3:7, Anisaldehyde).  
1H NMR (CDCl3, 400 MHz) δ 9.36 (s, 1 H; NH), 7.44-6.96 (m, 8 H; CH-Ar), 6.52 (m, 1 H; CH-Ar), 
5.21-5.07 (m, 0.4 H; OCH2 rotamer B), 5.14 (J = 12.9 Hz, 0.8 H; OCH2 rotamer A), 5.02 (d, J = 12.7 Hz, 0.8 
H; OCH2 rotamer A), 3.96 (m, 4 H; OCH3 and NCH2), 3.81 (d, J = 3.1 Hz, 1 H; CHN), 2.83 (t, J = 12.0 Hz; 
0.2 H; NCH2 rotamer B), 2.74 (t, J = 12.1 Hz, 0.8 H; NCH2 rotamer A), 2.63 (d, J = 3.1 Hz, 1H; COCH), 
2.15 (d, J = 14.1 Hz, 1 H; CH2), 1.89-1.64 (m, 4 H; CH2), 1.57 (m, 1 H; CH2), 0.81 (t, J = 7.0 Hz, 3 H; CH3). 
13C NMR (CDCl3, 100 MHz) (rotamers!) δ 188.3, 156.3, 154.8, 138.4, 136.5, 135.6, 128.4, 128.1, 128.0, 
127.5, 127.2, 127.2, 126.9, 119.2, 106.3, 106.0, 105.2, 105.1, 99.6, 99.5, 67.2, 66.9, 55.3, 45.8, 45.5, 41.7, 
41.3, 38.0, 36.5, 35.8, 26.3, 26.1, 25.1, 21.9, 21.8, 10.8. 
IR ν 3304 (w), 2959 (w), 2936 (w), 2875 (w), 1703 (s), 1620 (m), 1580 (m), 1517 (s), 1457 (m), 1410 
(s), 1364 (s), 1305 (w), 1259 (s), 1239 (w), 1208 (m), 1191 (m), 1162 (s), 1126 (m), 1108 (m), 1079 (w), 
1030 (w), 1010 (w), 981 (w), 911 (m), 824 (w), 776 (m), 735 (s), 699 (w). 
HRMS(ESI) calcd for C26H29N2O4+ (M+H) 433.2127, found 433.2110. 
 
Benzyl ethyl-11-methoxy-6-oxo-2,3,4,4a,5,6,7,11c-octahydro-1H-pyrido[3,2-c]carbazole-1-carboxylate 
(15c); ethyl-11-methoxy-3,4,4a,5,7,11c-hexahydro-1H-pyrido[3,2-c]carbazol-6(2H)-one (25c); benzyl 
4a-ethyl-8-methoxy-6-oxo-2,3,4,4a,5,6-hexahydroindolo[1,2-a][1,8]naphthyridine-1(12aH) carboxylate 
(16c) and 4a-ethyl-8-methoxy-1,2,3,4,4a,5-hexahydroindolo[1,2-a][1,8]naphthyridin-6(12aH)-one (26c) 
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The reaction was performed using general procedure GP2, starting from cyclopropane 1c (40 mg, 92 
μmol, 1.0 equiv) and copper (II) triflate (5.0 mg, 14 μmol, 0.15 equiv). The reaction was quenched after 15 
min and the crude oil was purified by column chromatography (PET/AcOEt 7:3, Anisaldehyde) to give the 
product 15c (Rf 0.18, 31 mg, 72 μmol, 78 %) and the product 16c (Rf 0.20, 4 mg, 9 μmol, 10%). The 
tetracyclic compound 15c (30 mg, 70 μmol, 1.0 equiv) was deprotected following the general procedure 
GP4 to give 25c (20 mg, 70 μmol, quant.) as a pale yellow oil without further purification. 
The reaction was performed following general procedure GP3, starting from cyclopropane 1c (40 mg, 92 
μmol, 1.0 equiv) and tosic acid (2.6 mg, 14 μmol, 0.15 equiv). The reaction was quenched after 15 min and 
the crude oil was purified by column chromatography (PET/AcOEt 8:2, Anisaldehyde) to give the product 
15c (Rf 0.18, 1.7 mg, 4 μmol, 4 %) and the product 16c (Rf 0.2, 35 mg, 81 μmol, 88 %). The tetracyclic 
compound 16c (30 mg, 70 μmol, 1.0 equiv) was deprotected following the general procedure GP4 to give 26c 
(20 mg, 68 μmol, quant) as a yellow oil without further purification. 
25c 
Rf 0.0 (AcOEt/PET 6:4 Anisaldehyde). 
1H NMR (CDCl3, 400 MHz) δ 9.44 (s br, 1 H; NH indole), 7.18 (t, J = 8.0 Hz, 1 H; CH-Ar), 6.92 (d, J = 
8.2 Hz, 1 H; CH-Ar), 6.47 (d, J = 7.8 Hz, 1 H; CH-Ar), 4.24 (s, 1 H; CHN), 3.97 (s, 3 H; OCH3), 3.29 (d, J 
= 16.9 Hz, 1 H; CH2CO), 3.19 (m, 1 H; CH2N), 2.85 (d, J = 11.3 Hz, 1 H; CH2N), 2.24 (d, J = 16.9 Hz, 1 H; 
CH2CO), 1.75 (m, 2 H; CH2), 1.62-1.41 (m, 3 H; CH2 and NH amine), 1.30 (m, 2 H; CH2), 0.80 (t, J = 7.5 
Hz, 3 H; CH3). 
13C NMR (CDCl3, 100 MHz) δ 191.1, 155.4, 139.5, 129.5, 127.8 116.6, 105.7, 99.9, 57.1, 55.5, 45.8, 
42.1, 40.3, 33.4, 31.5, 21.8, 7.7. (1 C in aromatic region is not resolved) 
IR ν 3267 (w), 2960 (w), 2932 (w), 1650 (s), 1620 (w), 1582 (m), 1543 (w), 1518 (w), 1470 (m), 1424 
(w), 1391 (w), 1354 (m), 1266 (w), 1254 (m), 1166 (w), 1108 (s), 977 (w), 919 (w), 873 (w), 785 (m), 740 
(s), 637 (m), 617 (s). 
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HRMS(ESI) calcd for C18H23N2O+ (M+H) 299.1760, found 299.1754. 
 26c 
Rf 0.2 (AcOEt/PET 4:6 Anisaldehyde). 
1H NMR (CDCl3, 400 MHz) δ 7.41 (s, 1 H; CH-Ar), 7.30 (t, J = 8.1 Hz, 1 H; CH-Ar), 6.99 (d, J = 8.3 
Hz, 1 H; CH-Ar), 6.51 (d, J = 7.7 Hz, 1 H; CH-Ar), 4.92 (s, 1 H; CHN), 3.94 (s, 3 H; OCH3), 3.35 (d, J = 
17.1 Hz, 1 H; CH2CO), 3.13 (m, 1 H; CH2N), 2.87 (t, J = 11.8 Hz, 1 H; CH2N), 2.29 (d, J = 17.1 Hz, 1 H; 
CH2CO), 1.87-1.49 (m, 5 H; CH2 and NH), 1.33 (m, 2 H; CH2), 0.80 (t, J = 7.5 Hz, 3 H; CH3).  
13C NMR (CDCl3, 100 MHz) δ 190.5, 155.5, 138.0, 131.2, 127.1, 118.9, 103.8, 102.4, 100.2, 70.7, 55.4, 
45.5, 40.8, 39.2, 32.9, 30.3, 21.7, 7.1. 
IR ν 2939 (w), 2862 (w), 1673 (s), 1615 (w), 1575 (w), 1525 (s), 1505 (w), 1463 (w), 1431 (w), 1368 
(w), 1307 (m), 1261 (s), 1182 (m), 1094 (w), 1038 (w), 983 (w), 924 (w), 911 (m), 773 (m), 735 (s). 
HRMS(ESI) calcd for C18H23N2O2+ (M+H) 299.1760, found 299.1762. 
 
4. Total synthesis of Goniomitine 
3-Triisopropylyloxyethyl-1H-indole (28) 
 
Following a reported procedure,[10] TIPSCl (630 mg, 3.25 mmol, 1.05 equiv) was added to a solution of 
Tryptophol (27) (500 mg, 3.10 mmol, 1.00 equiv) and imidazole (440 mg, 6.50 mmol, 2.10 equiv) in DMF 
(3.5 mL) at RT. The reaction was stirred for 1 hour then quenched with a saturated aqueous solution of 
NaHCO3 (5 mL). The organic layer was dried on Na2SO4 and concentrated under reduced pressure. The 
crude oil was purified by column chromatography (AcOEt/PET 1:9) to give the product 28 (990 mg, 3.10 
mmol, quant.) in quantitative yield. 
Rf 0.85 (AcOEt/PET 2:8 Anisaldehyde). 
1H NMR (CDCl3, 400 MHz) δ 7.95 (br s, 1H; NH ), 7.61 (d, J = 7.9 Hz, 1H; CH-Ar), 7.35 (d, J = 8.1 Hz, 
1 H; CH-Ar), 7.18 (ddd, J = 8.0 Hz, 7.1 Hz, 1.1 Hz, 1 H; CH-Ar), 7.11 (ddd, J = 8.0, 7.1, 1.1 Hz, 1 H; CH-
                                                     
[10] T. Fukuda, R. Maeda, M. Iwao, Tetrahedron, 1999, 55, 9151. 
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Ar), 7.06 (d, J = 1.7 Hz, 1H; CH-Ar), 3.95 (t, J = 7.4 Hz, 2 H; OCH2), 3.03 (m, 2 H; CH2), 1.14-1.00 (m, 21 
H; iPr). 
The 1H NMR corresponded with literature.[10] 
6-(3-Triisopropyloxyethyl-1H-indol-2-carbonyl)-5-ethyl-1-azabicyclo[4.1.0]heptane-1-
benzylcarboxylate (1d) 
 
 
tBuLi (1.6 M in pentane, 0.17 mL, 0.28 mmol, 3.0 equiv) was added dropwise into a solution of 3-
triisopropyloxyethyl-N-carboxylindole 29 (50 mg, 0.14 mmol, 1.5 equiv) prepared following GP5 and 
TMEDA (21 mg, 0.18 mmol, 2.0 equiv) in THF (1 mL) at -78° C. The solution was stirred over 3 hours then 
transferred via cannula into a solution of amide 11 (32 mg, 90 μmol, 1.0 equiv) in THF (1 mL) at 0°C over 
20 minutes. The reaction was stirred at 0°C during 20 minutes then transferred via cannula into a saturated 
aqueous solution of NaHCO3 (2 mL) at 0°C. The aqueous layer was extracted with Et2O (5x5 mL). The 
organic layers were dried over Na2SO4, evaporated under reduced pressure and purified on flash 
chromatography with deactivated silica (AcOEt/PET 1:9) to give amide 11 (8.2 mg, 23 μmol, 25%) and 1d 
(20 mg, 33 μmol, 36 % (48% brsm)) as a yellow oil. 
Rf 0.40 (AcOEt/PET 3:7, Anisaldehyde).  
1H NMR (CDCl3, 400 MHz) δ 9.84 (s, 0.2 H; NH rotamer B), 8.99 (s, 0.8 H; NH rotamer A), 7.70 (d, J = 
8.1 Hz, 1 H; CH-Ar), 7.45-7.30 (m, 4 H; CH-Ar), 7.25 (m, 1 H; CH-Ar), 7.20-7.08 (m, 3 H; CH-Ar), 5.28-
5.14 (m, 0.4 H; OCH2 rotamer B), 5.18 (d, J = 12.7 Hz, 0.8 H; OCH2 rotamer A), 5.09 (d, J = 12.8 Hz, 0.8 
H; OCH2 rotamer A), 4.06-3.81 (m, 4 H; CH2O, NCH2 and NCH), 3.52-3.25 (m, 2 H; CH2C-Ar), 2.84 (m, 
0.2 H; NCH2 rotamer B), 2.83 (d, J = 3.4 Hz, 0.8 H; CHCO rotamer A), 2.75 (t, J = 11.5 Hz, 0.8 H; NCH2 
rotamer A), 2.66 (d, J = 3.2 Hz, 0.2 H; CHCO rotamer B), 2.29 (m, 1 H; CH2), 1.91-1.55 (m, 5H; CH2), 
1.10-0.97 (m, 21 H; iPr), 0.86 (m, 3 H; CH3). 
13C NMR (CDCl3, 100 MHz) (rotamers!) δ 189.2, 156.2, 156.1, 136.6, 136.5, 135.9, 135.8, 133.6, 133.4, 
128.7, 128.5, 128.4, 128.4, 128.1, 128.0, 127.4, 127.2, 126.9, 126.0, 125.7, 120.9, 120.8, 120.1, 119.9, 
118.5, 118.3, 112.1, 112.0, 67.3, 66.8, 65.2, 64.1, 45.9, 44.5, 43.6, 41.7, 41.2, 38.2, 38.1, 37.5, 35.6, 29.4, 
29.2, 26.1, 25.9, 25.6, 25.3, 21.7, 21.3, 17.9, 17.8, 11.9, 10.7, 10.5. 
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IR ν 2943 (s), 2866 (m), 2852 (m), 1698 (s), 1556 (w), 1460 (m), 1432 (m), 1386 (w), 1340 (w), 1305 
(w), 1268 (m), 1193 (w), 1101 (s), 1013 (w), 919 (w), 884 (w), 820 (w), 744 (s), 695 (m), 633 (s). 
HRMS(ESI) calcd for C36H51N2O4Si+ (M+H) 603.3618, found 603.3782. 
Benzyl 4a-ethyl-6-oxo-7-(2-(triisopropylsilyloxy)ethyl)-2,3,4,4a,5,6-hexahydroindolo[1,2-
a][1,8]naphthyridine-1(12aH)-carboxylate (17) 
 
 
The reaction was performed following general procedure GP3, starting from cyclopropane 1d (60 mg, 0.10 
mmol, 1.0 equiv) and tosic acid (3.8 mg, 20 μmol, 0.2 equiv). The reaction was quenched after 10 min, 
extracted with Et2O (3x10 mL), washed with brine (2x10mL) and dried on Na2SO4. The organic layer was 
concentrate to give the cyclic product 17 (56 mg, 93 μmol, 93 %) as a yellow oil without further 
purification. 
Rf 0.75 (AcOEt/PET 2:8 Anisaldehyde). 
1H NMR (CDCl3, 400 MHz) δ 7.78 (d, J = 8.0 Hz, 1 H; CH-Ar), 7.51-7.34 (m, 5 H; CH-Ar), 7.19-7.09 
(m, 2 H; CH-Ar), 7.06 (d, J = 7.9 Hz, 1 H; CH-Ar), 6.43 (br s, 1 H; CHN), 5.39 (d, J = 11.3 Hz, 1 H; CH2-
Ar), 5.31 (d, J = 11.6 Hz, 1 H; CH2-Ar), 4.06 (m, 1 H; CH2N), 3.95 (m, 2 H; CH2O), 3.40 (m, 2 H; CH2C-
Ar), 2.67 (d, J = 16.0 Hz, 1 H; CHCO), 2.49 (d, J = 16.0 Hz, 1H; CHCO), 2.28 (td, J = 12.9 Hz, 2.7 Hz, 1H; 
CH2N), 1.84-1.52 (m, 5 H; CH2), 1.30 (m, 1 H; CH2), 1.13-0.83 (m, 24 H; iPr and CH3). 
13C NMR (CDCl3, 100 MHz) (rotamers!) δ 190.0, 155.4, 136.2, 135.6, 129.6, 128.8, 128.6, 128.4, 127.1, 
126.7, 122.5, 122.0, 121.1, 121.0, 120.5, 112.2, 111.8, 68.9, 68.0, 63.6, 47.5, 39.0, 38.6, 28.6, 28.2, 27.4, 
20.0, 17.9, 17.7, 11.9, 7.5. 
IR ν 2927 (s), 2863 (m), 1707 (s), 1676 (s), 1545 (m), 1463 (m), 1426 (s), 1346 (m), 1322 (w), 1275 (s), 
1217 (m), 1141 (w), 1114 (w), 1101 (s), 1055 (w), 1020 (w), 964 (w), 885 (w), 742 (s), 694 (m), 633 (m). 
HRMS(ESI) calcd for C18H23N2O2+ (M+H) 603.3618, found 603.3621. 
2-(4a-Ethyl-1,2,3,4,4a,5,6,12a-octahydro-indolo[1,2-a][1,8]naphthyridin-7-yl)-ethanol 
(Goniomitine)(3) 
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NaBH4 (49.0 mg, 1.30 mmol, 14.2 equiv) was added portionwise to a solution of tetracyclic compound 17 
(55 mg, 91 μmol, 1.0 equiv) in MeOH (3 mL) at 0°C. The reaction was allowed to warm to RT and stirred 
during 3 hours before adding 5 mL of ice water and extracting with DCM (5x5 mL). The organic layer was 
dried on Na2SO4 and concentrated under reduced pressure. The white solid obtained was solubilized with 
pyridine (1.2 mL) at rt. and Ac2O (0.8 mL) was added dropwise. The reaction was stirred overnight then 
quenched with NaHCO3 (5 mL) and extracted with DCM (3x5 mL). The organic layer was dried with 
Na2SO4 and concentrated to give pale yellow oil which was dissolved in EtOH (7 mL) and deprotected 
following the general procedure GP4. The crude oil obtained was diluted in THF (5 mL). The solution was 
stirred at RT and TBAF (0.4 mL, 0.4 mmol, 4.4 equiv) was added dropwise. The reaction was stirred 30 min 
at RT then quenched with water and extracted with DCM (3x5 mL). The organic layer was dried on Na2SO4, 
concentrated and purified on flash chromatography with deactivated silica (AcOEt/PET 1:1) to give 
goniomitine 3 (21 mg, 70 μmol, 77 % overall). 
Rf 0.2 (AcOEt/Hexane/Et3N 29:70:1 Anisaldehyde). 
1H NMR (CDCl3, 400 MHz) δ 7.52 (d, J = 7.7 Hz, 1 H; CH-Ar), 7.30 (d, J = 8.0 Hz, 1 H; CH-Ar), 7.14 
(t, J = 7.2 Hz, 1 H; CH-Ar), 7.08 (t, J = 7.5 Hz, 1 H; CH-Ar), 4.79 (s, 1 H; NCH), 3.83 (t, J = 6.4 Hz, 2 H; 
OCH2), 3.12-2.75 (m, 6 H; CH2), 2.52 (td, J = 13.1 Hz, 6.7 Hz, 1 H; CH2), 1.89 (d, J = 13.8 Hz, 1 H; CH2), 
1.80-1.41 (m, 7 H; CH2 OH and NH), 1.21 (m, 1 H; CH2), 0.88 (t, J = 7.5 Hz, 3 H; CH3). 
13C NMR (CDCl3, 125 MHz) δ 135.3, 132.7, 129.0, 120.5, 119.5, 118.0, 108.2, 105.9, 71.6, 62.6, 45.6, 
35.1, 34.0, 28.6, 27.8, 21.62, 21.58, 18.5, 7.1. 
IR ν 3317 (w), 2934 (s), 2857 (m), 1735 (w), 1651 (w), 1564 (w), 1463 (s), 1420 (w), 1360 (m), 1313 
(m), 1271 (w), 1240 (w), 1204 (w), 1118 (w), 1047 (m), 1017 (w), 910 (m), 872 (w), 740 (s), 648 (w). 
HRMS(ESI) calcd for C19H27N2O+ (M+H) 299.2123, found 299.2119. 
The obtained values for 1H NMR fitted perfectly with the reported ones for natural[11] and synthetic[12] 
goniomitine. The obtained values for 13C NMR fitted perfectly with the reported values for synthetic 
                                                     
[11] L. Randriambola, J. C. Quirion, C. Kanfan, H. P. Husson, Tetrahedron Lett. 1987, 28, 2123. 
[12] a) S. Takano, T. Sato, K. Inomata, K. Ogasawara, J. Chem. Soc. Chem. Commun. 1991, 462; b) C. L. Morales, B. L. 
Pagenkopf, Org. Lett. 2008, 10, 157. We thank Prof. Pagenkopf for a copy of the original NMR data. 
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goniomitine, but small differences were apparent when compared with natural goniomitine, probably due to 
different conditions of measurement. A comparison of the spectra is provided in section 6. 
5. Cell Assays[13] 
The MCF-7 (breast cancer), HCT116 (colon carcinoma), A549 (lung cancer) and PC-3M (prostate 
cancer) cell lines originate from the American Type Culture (ATCC) and were obtained as a generous gift 
from Dr. Markus Wartmann, Novartis AG, Switzerland. Cells were seeded at 1.5×103 per well into 96-well 
microtiter plates and incubated overnight. Compounds were added in serial dilutions on day 1. 
Subsequently, the plates were incubated for 72 h and then fixed with 3.3 % v/v glutaraldehyde, washed with 
water and stained with 0.05 % methylene blue. After washing, the dye was eluted with 3 % v/v HCl and the 
optical density measured at 665 nm with a photometer. IC50 values were determined by the GraphPad Prim 
software (San Diego, USA) using the formula (ODtreated-ODstart)/(ODcontrol-ODstart)×100. The IC50 is defined 
as the drug concentration which leads to 50 % of cells per well as compared to control cultures (100 %) at 
the end of the incubation period. Experiments were performed three times on different days. The MDCK 
cells (canine kidney) were obtained as a gift from Dr. Stefanie Krämer, ETH Zurich, Switzerland. The 
MDR-1-MDCK cells are a stably-transfected cell line expressing human P-glycoprotein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                     
[13] J. Gertsch, F. Feyen, A. Bützberger, B. Gerber, B. Pfeiffer, K. H. Altmann, Chembiochem 2009, 10, 2513. 
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Crystallographic data 
 
Table 1.  Crystal data and structure refinement for fds330. 
Identification code  fds330 
Empirical formula  C17 H21 Cl N2 O 
Formula weight  304.81 
Temperature  140(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 9.1506(10) Å α= 90°. 
 b = 15.3882(14) Å β= 103.618(12)°. 
 c = 10.9477(12) Å γ = 90°. 
Volume 1498.2(3) Å3 
Z 4 
Density (calculated) 1.351 Mg/m3 
Absorption coefficient 0.256 mm-1 
F(000) 648 
Crystal size 0.15 x 0.11 x 0.09 mm3 
Theta range for data collection 2.93 to 26.37°. 
Index ranges -11<=h<=11, -19<=k<=19, -13<=l<=13 
Reflections collected 13092 
Independent reflections 3040 [R(int) = 0.0708] 
Completeness to theta = 26.37° 99.1 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.92803 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3040 / 0 / 274 
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Goodness-of-fit on F2 0.967 
Final R indices [I>2sigma(I)] R1 = 0.0546, wR2 = 0.0992 
R indices (all data) R1 = 0.1022, wR2 = 0.1112 
Largest diff. peak and hole 0.380 and -0.237 e.Å-3 
 
Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for fds330.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
Cl(1) 2806(1) 4005(1) 4618(1) 27(1) 
O(1) -709(2) 5221(1) 1532(2) 28(1) 
N(1) 3748(3) 5933(2) 4836(2) 19(1) 
N(2) 2019(3) 5647(2) 754(2) 20(1) 
C(1) 2842(3) 6581(2) 3930(2) 17(1) 
C(2) 3758(3) 6081(2) 6187(3) 23(1) 
C(3) 2167(3) 6082(2) 6324(3) 24(1) 
C(4) 1247(3) 6764(2) 5501(3) 21(1) 
C(5) 1213(3) 6668(2) 4094(2) 18(1) 
C(6) 273(3) 5867(2) 3555(2) 18(1) 
C(7) 317(3) 5612(2) 2231(2) 20(1) 
C(8) 1700(3) 5838(2) 1889(2) 17(1) 
C(9) 2867(3) 6294(2) 2628(2) 17(1) 
C(10) 3988(3) 6389(2) 1933(2) 17(1) 
C(11) 3410(3) 5976(2) 759(2) 18(1) 
C(12) 4208(3) 5956(2) -184(3) 23(1) 
C(13) 5577(3) 6356(2) 69(3) 27(1) 
C(14) 6179(3) 6768(2) 1222(3) 26(1) 
C(15) 5402(3) 6784(2) 2151(3) 22(1) 
C(16) 521(3) 7495(2) 3402(3) 23(1) 
C(17) -898(3) 7839(2) 3712(3) 28(1) 
________________________________________________________________________________  
 
 Table 3.   Bond lengths [Å] and angles [°] for  fds330. 
_____________________________________________________  
O(1)-C(7)  1.221(3) 
N(1)-C(2)  1.495(3) 
N(1)-C(1)  1.510(3) 
N(1)-H(1A)  0.91(3) 
N(1)-H(1B)  0.95(3) 
N(2)-C(11)  1.369(3) 
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N(2)-C(8)  1.373(3) 
N(2)-H(2)  0.88(3) 
C(1)-C(9)  1.497(4) 
C(1)-C(5)  1.548(3) 
C(1)-H(1)  1.00(2) 
C(2)-C(3)  1.498(4) 
C(2)-H(2A)  0.94(3) 
C(2)-H(2B)  0.93(3) 
C(3)-C(4)  1.504(4) 
C(3)-H(3A)  0.88(3) 
C(3)-H(3B)  1.00(2) 
C(4)-C(5)  1.541(4) 
C(4)-H(4A)  0.98(2) 
C(4)-H(4B)  0.96(3) 
C(5)-C(16)  1.539(4) 
C(5)-C(6)  1.540(4) 
C(6)-C(7)  1.511(4) 
C(6)-H(6A)  0.97(3) 
C(6)-H(6B)  0.97(3) 
C(7)-C(8)  1.444(4) 
C(8)-C(9)  1.371(3) 
C(9)-C(10)  1.422(4) 
C(10)-C(15)  1.398(4) 
C(10)-C(11)  1.420(4) 
C(11)-C(12)  1.398(4) 
C(12)-C(13)  1.364(4) 
C(12)-H(12)  0.94(2) 
C(13)-C(14)  1.404(4) 
C(13)-H(13)  0.84(3) 
C(14)-C(15)  1.371(4) 
C(14)-H(14)  0.93(3) 
C(15)-H(15)  0.99(3) 
C(16)-C(17)  1.513(4) 
C(16)-H(16A)  0.96(3) 
C(16)-H(16B)  0.95(3) 
C(17)-H(17A)  0.92(3) 
C(17)-H(17B)  0.95(3) 
C(17)-H(17C)  0.96(3) 
 
C(2)-N(1)-C(1) 115.0(2) 
C(2)-N(1)-H(1A) 104.3(15) 
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C(1)-N(1)-H(1A) 112.1(16) 
C(2)-N(1)-H(1B) 106.6(19) 
C(1)-N(1)-H(1B) 108.9(19) 
H(1A)-N(1)-H(1B) 110(2) 
C(11)-N(2)-C(8) 108.3(2) 
C(11)-N(2)-H(2) 123(2) 
C(8)-N(2)-H(2) 129(2) 
C(9)-C(1)-N(1) 107.5(2) 
C(9)-C(1)-C(5) 111.5(2) 
N(1)-C(1)-C(5) 112.1(2) 
C(9)-C(1)-H(1) 108.7(12) 
N(1)-C(1)-H(1) 104.7(12) 
C(5)-C(1)-H(1) 111.9(12) 
N(1)-C(2)-C(3) 108.6(2) 
N(1)-C(2)-H(2A) 105.5(15) 
C(3)-C(2)-H(2A) 111.8(15) 
N(1)-C(2)-H(2B) 103.2(15) 
C(3)-C(2)-H(2B) 111.5(16) 
H(2A)-C(2)-H(2B) 115(2) 
C(2)-C(3)-C(4) 111.1(2) 
C(2)-C(3)-H(3A) 105(2) 
C(4)-C(3)-H(3A) 109.8(19) 
C(2)-C(3)-H(3B) 107.9(14) 
C(4)-C(3)-H(3B) 110.2(14) 
H(3A)-C(3)-H(3B) 113(2) 
C(3)-C(4)-C(5) 114.1(2) 
C(3)-C(4)-H(4A) 109.8(13) 
C(5)-C(4)-H(4A) 106.3(13) 
C(3)-C(4)-H(4B) 107.8(16) 
C(5)-C(4)-H(4B) 110.4(16) 
H(4A)-C(4)-H(4B) 108(2) 
C(16)-C(5)-C(6) 110.2(2) 
C(16)-C(5)-C(4) 108.8(2) 
C(6)-C(5)-C(4) 109.7(2) 
C(16)-C(5)-C(1) 108.1(2) 
C(6)-C(5)-C(1) 110.6(2) 
C(4)-C(5)-C(1) 109.4(2) 
C(7)-C(6)-C(5) 115.9(2) 
C(7)-C(6)-H(6A) 103.7(14) 
C(5)-C(6)-H(6A) 109.9(14) 
C(7)-C(6)-H(6B) 109.7(14) 
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C(5)-C(6)-H(6B) 105.7(14) 
H(6A)-C(6)-H(6B) 112(2) 
O(1)-C(7)-C(8) 123.2(2) 
O(1)-C(7)-C(6) 122.6(2) 
C(8)-C(7)-C(6) 114.2(2) 
C(9)-C(8)-N(2) 110.0(2) 
C(9)-C(8)-C(7) 125.3(2) 
N(2)-C(8)-C(7) 124.7(2) 
C(8)-C(9)-C(10) 107.2(2) 
C(8)-C(9)-C(1) 121.9(2) 
C(10)-C(9)-C(1) 130.8(2) 
C(15)-C(10)-C(11) 118.8(2) 
C(15)-C(10)-C(9) 135.2(3) 
C(11)-C(10)-C(9) 106.1(2) 
N(2)-C(11)-C(12) 129.5(3) 
N(2)-C(11)-C(10) 108.4(2) 
C(12)-C(11)-C(10) 122.0(2) 
C(13)-C(12)-C(11) 117.0(3) 
C(13)-C(12)-H(12) 123.9(15) 
C(11)-C(12)-H(12) 119.0(15) 
C(12)-C(13)-C(14) 122.2(3) 
C(12)-C(13)-H(13) 120.3(18) 
C(14)-C(13)-H(13) 117.4(18) 
C(15)-C(14)-C(13) 120.8(3) 
C(15)-C(14)-H(14) 117.9(17) 
C(13)-C(14)-H(14) 121.3(17) 
C(14)-C(15)-C(10) 119.1(3) 
C(14)-C(15)-H(15) 121.5(15) 
C(10)-C(15)-H(15) 119.3(15) 
C(17)-C(16)-C(5) 117.0(3) 
C(17)-C(16)-H(16A) 106.6(16) 
C(5)-C(16)-H(16A) 110.0(16) 
C(17)-C(16)-H(16B) 109.6(17) 
C(5)-C(16)-H(16B) 109.2(16) 
H(16A)-C(16)-H(16B) 104(2) 
C(16)-C(17)-H(17A) 109.4(17) 
C(16)-C(17)-H(17B) 111.3(17) 
H(17A)-C(17)-H(17B) 110(2) 
C(16)-C(17)-H(17C) 110.1(17) 
H(17A)-C(17)-H(17C) 108(2) 
H(17B)-C(17)-H(17C) 108(2) 
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_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
  
 Table 4.   Anisotropic displacement parameters  (Å2x 103) for fds330.  The anisotropic 
displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
Cl(1) 20(1)  26(1) 35(1)  -2(1) 7(1)  -2(1) 
O(1) 19(1)  45(1) 18(1)  -11(1) 3(1)  -12(1) 
N(1) 17(1)  22(1) 17(1)  -1(1) 2(1)  -1(1) 
N(2) 18(1)  31(1) 12(1)  -5(1) 3(1)  -4(1) 
C(1) 15(1)  18(1) 16(2)  -2(1) 2(1)  -5(1) 
C(2) 29(2)  26(2) 12(2)  -2(1) 1(1)  -2(1) 
C(3) 26(2)  34(2) 11(2)  -2(1) 4(1)  -4(1) 
C(4) 20(2)  26(2) 17(2)  -6(1) 6(1)  -6(1) 
C(5) 16(1)  23(1) 17(2)  -3(1) 5(1)  -2(1) 
C(6) 16(2)  22(2) 17(2)  -1(1) 5(1)  -2(1) 
C(7) 21(2)  24(1) 15(2)  1(1) 4(1)  1(1) 
C(8) 19(1)  23(1) 10(1)  -1(1) 4(1)  -1(1) 
C(9) 17(1)  21(1) 14(1)  1(1) 6(1)  1(1) 
C(10) 17(1)  20(1) 15(1)  4(1) 3(1)  4(1) 
C(11) 17(1)  20(1) 17(1)  3(1) 1(1)  4(1) 
C(12) 25(2)  30(2) 15(2)  1(1) 7(1)  5(1) 
C(13) 24(2)  34(2) 28(2)  6(1) 18(2)  7(1) 
C(14) 19(2)  31(2) 29(2)  4(1) 9(1)  -1(1) 
C(15) 17(2)  26(2) 21(2)  0(1) 4(1)  -1(1) 
C(16) 24(2)  23(2) 22(2)  -1(1) 5(1)  -3(1) 
C(17) 23(2)  31(2) 29(2)  -1(2) 7(2)  1(2) 
______________________________________________________________________________  
 
 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for fds330. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1A) 3400(30) 5384(17) 4680(20) 10(6) 
H(1B) 4760(40) 5960(20) 4780(30) 50(10) 
H(2) 1480(30) 5340(20) 120(30) 40(10) 
H(1) 3410(20) 7140(14) 4114(19) 0(5) 
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H(2A) 4220(30) 6627(17) 6390(20) 17(7) 
H(2B) 4290(30) 5608(17) 6590(20) 15(7) 
H(3A) 2230(30) 6205(18) 7120(30) 33(9) 
H(3B) 1730(30) 5493(17) 6090(20) 12(6) 
H(4A) 1660(30) 7341(16) 5750(20) 9(6) 
H(4B) 250(30) 6741(17) 5630(20) 23(7) 
H(6A) 660(30) 5355(17) 4050(20) 14(7) 
H(6B) -750(30) 6003(16) 3590(20) 16(7) 
H(12) 3810(30) 5644(16) -930(20) 13(7) 
H(13) 6110(30) 6345(16) -460(20) 15(7) 
H(14) 7100(30) 7047(18) 1370(30) 28(8) 
H(15) 5840(30) 7044(16) 2990(20) 20(7) 
H(16A) 1240(30) 7961(18) 3560(20) 28(8) 
H(16B) 350(30) 7405(16) 2520(30) 24(8) 
H(17A) -1560(30) 7390(17) 3700(20) 21(8) 
H(17B) -1360(30) 8270(19) 3130(30) 28(8) 
H(17C) -670(30) 8095(18) 4530(30) 26(8) 
________________________________________________________________________________  
 
Table 6.  Torsion angles [°] for fds330. 
________________________________________________________________  
C(2)-N(1)-C(1)-C(9) -175.9(2) 
C(2)-N(1)-C(1)-C(5) -52.9(3) 
C(1)-N(1)-C(2)-C(3) 57.1(3) 
N(1)-C(2)-C(3)-C(4) -57.6(3) 
C(2)-C(3)-C(4)-C(5) 57.6(3) 
C(3)-C(4)-C(5)-C(16) -168.6(2) 
C(3)-C(4)-C(5)-C(6) 70.7(3) 
C(3)-C(4)-C(5)-C(1) -50.8(3) 
C(9)-C(1)-C(5)-C(16) -74.1(3) 
N(1)-C(1)-C(5)-C(16) 165.3(2) 
C(9)-C(1)-C(5)-C(6) 46.6(3) 
N(1)-C(1)-C(5)-C(6) -74.0(3) 
C(9)-C(1)-C(5)-C(4) 167.5(2) 
N(1)-C(1)-C(5)-C(4) 46.9(3) 
C(16)-C(5)-C(6)-C(7) 68.6(3) 
C(4)-C(5)-C(6)-C(7) -171.6(2) 
C(1)-C(5)-C(6)-C(7) -50.9(3) 
C(5)-C(6)-C(7)-O(1) -153.3(3) 
C(5)-C(6)-C(7)-C(8) 29.2(3) 
C(11)-N(2)-C(8)-C(9) 0.5(3) 
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C(11)-N(2)-C(8)-C(7) 178.7(2) 
O(1)-C(7)-C(8)-C(9) 178.3(3) 
C(6)-C(7)-C(8)-C(9) -4.2(4) 
O(1)-C(7)-C(8)-N(2) 0.3(4) 
C(6)-C(7)-C(8)-N(2) 177.8(2) 
N(2)-C(8)-C(9)-C(10) -0.6(3) 
C(7)-C(8)-C(9)-C(10) -178.9(2) 
N(2)-C(8)-C(9)-C(1) -179.2(2) 
C(7)-C(8)-C(9)-C(1) 2.6(4) 
N(1)-C(1)-C(9)-C(8) 98.6(3) 
C(5)-C(1)-C(9)-C(8) -24.6(3) 
N(1)-C(1)-C(9)-C(10) -79.6(3) 
C(5)-C(1)-C(9)-C(10) 157.2(3) 
C(8)-C(9)-C(10)-C(15) 179.4(3) 
C(1)-C(9)-C(10)-C(15) -2.2(5) 
C(8)-C(9)-C(10)-C(11) 0.5(3) 
C(1)-C(9)-C(10)-C(11) 178.9(2) 
C(8)-N(2)-C(11)-C(12) -179.1(3) 
C(8)-N(2)-C(11)-C(10) -0.1(3) 
C(15)-C(10)-C(11)-N(2) -179.4(2) 
C(9)-C(10)-C(11)-N(2) -0.3(3) 
C(15)-C(10)-C(11)-C(12) -0.3(4) 
C(9)-C(10)-C(11)-C(12) 178.8(2) 
N(2)-C(11)-C(12)-C(13) 178.7(3) 
C(10)-C(11)-C(12)-C(13) -0.2(4) 
C(11)-C(12)-C(13)-C(14) 0.4(4) 
C(12)-C(13)-C(14)-C(15) 0.0(4) 
C(13)-C(14)-C(15)-C(10) -0.5(4) 
C(11)-C(10)-C(15)-C(14) 0.7(4) 
C(9)-C(10)-C(15)-C(14) -178.2(3) 
C(6)-C(5)-C(16)-C(17) 74.6(3) 
C(4)-C(5)-C(16)-C(17) -45.7(3) 
C(1)-C(5)-C(16)-C(17) -164.4(3) 
________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
  
 Table 7.  Hydrogen bonds for fds330  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 N(1)-H(1A)...Cl(1) 0.91(3) 2.19(3) 3.082(3) 170(2) 
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 N(1)-H(1B)...Cl(1)#1 0.95(3) 2.17(3) 3.069(2) 159(3) 
 N(2)-H(2)...O(1)#2 0.88(3) 1.98(3) 2.841(3) 164(3) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,-y+1,-z+1    #2 -x,-y+1,-z       
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13C NMR (CDCl3, 125 MHz) δ 135.34, 132.70, 129.01, 120.52, 119.50, 118.05, 108.20, 105.88, 71.55, 62.57, 
45.62, 35.06, 33.99, 28.61, 27.68, 21.62, 21.58, 18.54, 7.07. 
Pagenkopf (values kindly provided by Prof. Pagenkopf):[12b] 13C NMR (CDCl3, 100 MHz) δ 135.35, 132.70, 
129.04, 120.51, 119.51, 118.05, 108.18, 105.99, 71.51, 62.52, 35.07, 33.98, 28.61, 27.67, 21.65, 21.55, 
18.52, 7.05. 
 
Husson:[11] 13C NMR (CDCl3, 100 MHz) δ 135.4, 132.6, 129.3, 120.8, 119.9, 118.1, 108.7, 106.8, 71.1, 62.6, 
45.4, 35.3, 33.8, 28.7, 27.8, 21.8, 20.8, 18.5, 7.3. 
CDCl3 = 77.0 ppm 
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1H NMR (CDCl3, 400 MHz) δ 7.52 (d, J = 7.7 Hz, 1 H; CH-Ar), 7.30 (d, J = 8.0 Hz, 1 H; CH-Ar), 7.14 
(t, J = 7.2 Hz, 1 H; CH-Ar), 7.08 (t, J = 7.5 Hz, 1 H; CH-Ar), 4.79 (s, 1 H; NCH), 3.83 (t, J = 6.4 Hz, 2 H; 
OCH2), 3.12-2.75 (m, 6 H; CH2), 2.52 (td, J = 13.1 Hz, 6.7 Hz, 1 H; CH2), 1.89 (d, J = 13.8 Hz, 1 H; CH2), 
1.80-1.41 (m, 7 H; CH2 OH and NH), 1.21 (m, 1 H; CH2), 0.88 (t, J = 7.5 Hz, 3 H; CH3). 
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